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ABSTRACT 
UNIVERSAL SWINE INFLUENZA ANTIGEN AND VACCINE 
ZHAO WANG 
2018 
 Swine influenza A viruses pose a serious concern for global health and 
worldwide swine industry considering their evasion from vaccine-induced 
immune responses. Formulation of effective influenza vaccines can be 
complicated by both antigenic shift to a different subtype of hemagglutinin (HAs) 
and antigenic drift within a particular HA subtype. To address these concerns, we 
employed a systematic approach to determine the antigenic determinants of 
swine influenza A viruses by focusing on H1 and H3 subtypes. In parallel, we 
used a cross-disciplinary approach including structural biology and modeling, 
virology, and immunology to identify swine influenza A virus-derived HA fusion 
intermediates broadly reactive to antibodies elicited from various strains or 
subtypes of swine influenza A viruses. Finally, we conducted a swine influenza 
vaccine study to evaluate the protective efficacy of a newly identified HA fusion 
intermediate. The vaccine candidate, when administered into pigs, protected 
swine against infections by swine influenza H1N1 and H3N2 viruses.  
 For the antigenicity study, we performed a detailed analysis of the 
antigenic determinants of the Hemagglutinin (HA) protein of pdm09 strain 
(subtype H1N1) by the HA peptide array in Enzyme-linked immunosorbent assay 
 
xvii 
with immune serum from experimental infected pigs by swine influenza A viruses 
(SIVs). The peptide array contains 139 peptides spanning the HA protein of 
H1N1pdm09 and peptides are 14- or 15-mers with 11 amino acid overlaps. A 
panel of swine antisera against SIV H1 clusters α, β, γ, δ-A, δ-B, H1N1pdm09, 
and H3 cluster was used in this study and SIVs used for swine hyperimmune 
sera production are representative subtypes and clusters of SIV circulating in 
North America. The results of these studies identified three immunodominant 
peptides, one located in the HA1 (amino acids 57-71) and two in the HA2 (amino 
acids 481-495 and 553-566), reactive to its homologous antisera (H1N1pdm09). 
Analysis of peptide reactivity with heterologous serum samples revealed that 
antibody responses to two HA2 peptides (amino acids 481-495 and 553-566) are 
completely conserved among antisera of all H1 clusters. In addition to 
H1N1pdm09, HA1 peptide (amino acids 57-71) was reactive to SIV H1 γ antisera 
Interestingly, none of peptides in HA peptide array of H1N1pdm09 were reactive 
to SIV H3 antisera, despite that this antisera has a HI antibody titer similar to 
those of H1 clusters antisera. Structural modeling localized two conserved 
immunedominant determinants to the membrane 
proximal external region (MPER) (amino acids 481-495) and the intracytoplasmic 
tail (amino acids 553-566) of the HA molecule.  
 For the HA fusion intermediate project, through a structure-guided site-
specific mutagenesis targeting HA2 A and CD helical domains, we identified a 
mutation, named N439G, that attenuated viral replication but the resultant virus 
was still recognized by antiviral antibodies. The attenuation was mediated 
 
xviii 
probably through the disruption of triple CD helix formation in the viruses. In light 
of the fact that N439G virus is highly attenuated in that it may prolong the 
exposure of HA fusion intermediate to host B cells toward antibody production, 
we next evaluated its vaccination efficacy in pigs.  Significantly, pigs receiving 
N439G immunizations were substantially protected from both swine influenza A 
H1N1 and H3N2. 
 In summary, the results of our antigenicity study provide an important 
foundation for further analyzing the immune response against these B cell 
epitopes residing in the HA protein during natural SIV infection and also provide 
potential peptide substrates for diagnostic assays and for vaccine strategies. Our 
universal vaccine candidate identified from this work should pave the way for 
further studies toward developing a universal swine influenza vaccine and 
defining a protective mechanism.   
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CHAPTER 1. INTRODUCTION AND OBJECTIVES 
 
1.1 Introduction 
 Influenza remains a big threat to global health and livestock industry. 
There are four types of influenza viruses identified to date. Among them, 
influenza A virus (IAV) is the most "successful" genus due to its ability to 
frequently alter its segments, thereby resulting in both antigenic drift and shift. 
The derived mutant influenza viruses are new to humans and animals with no 
pre-existing immunity, which as a result cause annual influenza epidemics and 
occasional influenza pandemics. IAV has numerous subtypes depending on 
surface proteins hemagglutinin (H1-H17) and neuraminidase (NA1-NA11). The 
diversity among influenza virus subtypes and seasonal strains carrying novel 
mutations poses a big challenge to develop effective vaccines that offers a solid 
protection against all strains. Although the current multivalent IAV vaccine is 
helpful to prevent seasonal outbreaks, there is an urgent call for more effective 
vaccine that can provide broad protection against multiple IAV strains. Currently, 
human seasonal IAV subtypes consist of H1 and H3 HA subtypes, and the N1 
and N2 NA subtypes. In the past, pandemic IAV include the H2 HA.  Influenza 
viruses with other HA subtypes are occasionally able to infect humans, such as 
“bird flu” H5N1 virus, however, such spillover infections are rare and there is no 
evidence for sustainable human-to-human transmission.  
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 Swine influenza A viruses pose a concern for global health and worldwide 
swine industry. Recent example of human influenza pandemic caused by the 
swine-origin triple reassortmant virus in 2009 has demonstrated the devastating 
public health consequence. Swine is commonly infected by IAV, primarily 
subtypes H1N1, H1N2, and H3N2 (Brockwell-Staats et al., 2009; Vincent et al., 
2017). H1 subtype of SIV has further evolved into clusters α, β, γ, δ-A, δ-B, δ-C, 
δ-D, δ-E, and 2009 pandemic H1N1 virus. H3 subtypes has clusters of I, II, III 
and IV (Hause et al., 2012). The serum from SIV infected pig has very variable 
neutralization activities to SIV strains of the same HA subtype with different 
cluster (Hause et al., 2012). The diversity among influenza virus subtypes and 
seasonal strains emerged due to mutations makes it difficult to develop a 
universal vaccine that offers protection against all SIV strains. Protection efficacy 
of influenza vaccines can be complicated by both antigenic shift to a different 
subtype of HA and antigenic drift within a particular HA subtype.  
 The research conducted in this dissertation had been focused on 
identifying critical antigenic determinants of HA proteins of circulating SIV strains 
in the North America, and developing universal (broadly-reactive) vaccine against 
contemporary SIV strains. Currently, the IAV vaccine development primarily aims 
to elicit immune responses towards the globular head domain of the HA to elicit 
antibodies that are able to block binding of the virus to membrane receptors on 
the host cells. Our hypothesis was that vaccine targeting the highly conserved 
region of the SIV HA stem domain could generate immunity against a broad 
spectrum of influenza strains. Another hypothesis was that viruses with 
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attenuated replication capacity through a slow fusion kinetic may prolong its HA 
protein exposed to immune system so broadly active antibodies against the 
conserved entry mechanism can be generated, which as a result protect swine 
against infections by multiple strains or subtypes. 
 
1.2 Objectives 
The first objective of this dissertation was to conduct a detailed mapping of the 
linear B cell epitopes of the Hemagglutinin (HA) protein of Influenza H1N1pdm09 
virus by using synthetic peptide array approach, while the second objective 
involved studies to characterize a role of N-terminal HA stem region of swine 
influenza A virus including the helix A, B loop, and CD helix in virus replication in 
both cell lines and primary porcine tracheal epithelial cells (PTEpC). The other 
component of the second objective was to evaluate protective efficacy of an 
attenuated virus with a mutation in the CD helix in pigs.  
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CHAPTER 2. LITERATURE REVIEW 
 
2.1 Classification of Influenza viruses 
 Influenza viruses belong to Orthomyxovirus family of enveloped, negative 
sense ssRNA viruses. According to the genetic and biological properties of the 
viruses, the ICTV classified the Orthomyxoviridae family into seven genus: 
Alphainfluenzavirus, Betainfluenzavirus, Gammainfluenzvirus, 
Deltainfluenzavirus, Isavirus, Thogotovirus and Quaranjavirus (ICTV, 2018; 
Lefkowitz et al., 2018). Influenza viruses types A, B, and C have distinct antigenic 
properties residing in two major structural proteins (matrix 1 and nucleocapsid) 
(Palese & Shaw, 2007). Recently, a new type of influenza virus with bovines as a 
primary reservoir, designated influenza type D, has been described (Hause et al., 
2014; Hause et al., 2013).  All the types of influenza virions are enveloped, and 
have negative-sensed, single-stranded RNA genomes (Figure 1). Both types A 
and B have eight genome segments (Table 1), and both types C and D contain 
seven genome segments (Table 2). Each segment encodes at least 1 viral gene. 
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Figure 1. Diagrammatic illustration of the influenza A virion  
The nucleocapsid core (viral ribonucleoprotein, vRNP) contains the eight-segmented 
negative sense RNA genome of the IAV and surrounding viral proteins. These segments 
are assumed to link together to form a helix during virus assembles at the cell surface. 
Underneath the viral envelope is a layer of M1.  
 
Table 1. Genomes and Proteomes of Influenza A and B Viruses 
Segment Length(nt) Protein(s) encoded Gene Function 
1  ~2.34K PB2 RNA synthesis 
2 ~2.34K PB1 RNA synthesis 
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Note: IAV PB1 segment encodes PB1 and PB1-F2; IBV NA segment encodes NA and NB. 
 
Table 2. Genomes and Proteomes of Influenza C and D Viruses 
3 ~2.23K PA RNA synthesis 
4 ~2.07K HA Sialic acid binding; membrane fusion 
5 ~1.57K NP RNA encapsidation; replication 
6 ~1.41K NA Receptor destruction 
7 ~1.03K 
M1 Viral assembly and budding 
M2 Ion channel 
8 ~0.93K 
NS1 Innate immunity antagonism 
NS2 Nuclear exportation factor 
Segment Length(nt) Protein(s) encoded Gene Function 
1  ~2.37K PB2 RNA synthesisa 
2 ~2.36K PB1 RNA synthesisa 
3 ~2.18K P3 RNA synthesisa 
4 ~2.07K HEF Sialic acid binding; receptor destruction; membrane fusion  
5 ~1.81K NP RNA encapsidation; replicationa 
6 ~1.18K 
M1 Viral assemblya 
M2 Ion channela 
7 ~0.93K 
NS1 Innate immunity antagonisma 
NS2 Nuclear exportation factora 
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Note: superscripts "a" indicate the gene functions for IDV are predicted based on the 
similarities between the genes of ICV and IDV and therefore are to be further validated by 
future structural and biological studies. 
 IAVs are further classified into many subtypes based on antigenicity of 
surface glycoproteins hemagglutinin (HA) and neuraminidase (NA).  To date, 18 
subtypes of HA (H1-H18) and 11 NA (N1-N11) have been described (Shao et al., 
2017; Tong et al., 2013). Influenza B viruses (IBV) have evolved into two 
antigenically and genetically distinct lineages, Yamagata and Victoria 
(Vijaykrishna et al., 2015). Influenza C viruses (ICV) have six antigenic lineages, 
namely C/Taylor, C/Mississippi, C/Aichi, C/Yamagata, C/Kanagawa, and C/Sao 
Paulo (Matsuzaki et al., 2016). IDV have evolved into two lineages represented 
by D/swine/Oklahoma/1334/2011 (D/OK) and D/bovine/Oklahoma/660/2013 
(D/660)(Collin et al., 2015). 
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2.2 Influenza A Virus Replication 
 
Figure 2. Schematic diagram of the influenza viral life cycle 
The life cycle of the influenza virus can be divided into the following steps (i) attachment 
(receptor binding); (ii) endosomal internalization of the virus into cell (endocytosis); (iii) 
uncoating, cytoplasmic transport and nuclear import of viral ribonucleoproteins (vRNPs); 
(iv) transcription and replication of the viral RNAs; (v) nuclear exportation and protein 
synthesis; (vi) viral progeny assembly, budding and release from the cell membrane (Wu 
et al., 2017). 
2.2.1 Early stage: Viral attachment, internalization, fusion and uncoating 
 The binding of the influenza virus to the cellular receptor on a susceptible 
cell is the very beginning of IAV replication cycle. The viral spike formed by HA 
proteins of IAV binds to the receptor: sialic acid residues present on cellular 
glycoproteins (Lanzrein et al., 1994). The attachment of the virus to the cell 
induces endocytosis using the clathrin- and caveolin-dependent mechanisms 
(Fontana et al., 2012). Membrane fusion occurs at late endosomes. The low pH 
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of late endosome (pH 5-6) triggers HA conformation change, resulting in the 
fusion between the viral and endosomal membranes. Endosome provides 
protons for IAV M2 ion channel and the acidification of internal virion results in 
conformational change in the M1, which then weakens interactions between M1 
and the viral ribonucleoproteins (vRNPs). In the late endosome, the pre-acidified 
viral core is subsequently exposed to a high concentration of K(+), which then 
interrupts the interactions between the vRNPs. Finally, the destabilized viral 
cores are delivered to the cytosol, and the released polymerase complex and 
RNA genome become competent and infectious (Stauffer et al., 2014).  
2.2.2 Middle stage: Transcription and replication of viral genome 
 IAV utilizes “cap-snatching” mechanism to hijack the host’s transcription 
machinery and replicates own viral genome. Specifically, it needs to cleave the 
cellular mRNAs’ 10 to 15 nucleotides 3’ to the cap structure. This cellular capped 
RNA fragment is bound by PB2 cap-binding domain and the 5’ cap of host mRNA 
is then removed by PA and subsequently used by the viral polymerase complex 
to prime viral transcription. Addition of the 5’ cap and polyadenylation of the 3’ 
end of the positive sense RNA yield mature IAV mRNAs. In contrast, exact 
replication of the viral RNA genome yields viral complimentary RNA, which is 
then used as template to yield vRNAs, which can be packaged into progeny 
virus.  Segments 1-6 encode one protein each and segments 7 and 8 encode for 
two proteins each due to splicing. Bicistronic segment 7 produces mRNAs that 
are spliced to produce M1 and M2. Similarly, segment 8 produces mRNAs of 
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NS1 and NS2 (Samji, 2009). The viral ribonucleoprotein complex (vRNP), which 
comprises NP homo-oligomer, three polymerase subunit proteins (PB2, PB1, and 
PA) and viral RNA (vRNA), are then exported from the nucleus. It is 
hypothesized that M1's binding to the vRNPs and NS2 is involved in the process 
(Samji, 2009). 
2.2.3 Late stage: Assembly and budding 
 IAV forms viral particles at the host cell plasma membrane after the vRNP 
accumulates in the cytosol. Virus particles bud from the apical side of polarized 
cells, such as airway epithelial cells (Nayak et al., 2004). Membrane proteins HA, 
NA, and M2 are transported to the apical plasma membrane. It has been 
reported that the HA, NA and M2 proteins that anchor on the cell membranes are 
able to interact with viral proteins present in cytosol, especially M1 and NP, to 
recruit M1 and vRNP to the site for assembly (Rossman & Lamb, 2011; Wang et 
al., 2010a). It has been shown that the tail of M2 is extremely important in the 
formation of viral particles, and both HA and NA are required to deform the cell 
membrane and the initiation of the virus budding event (Rossman & Lamb, 2011; 
Wang et al., 2010a). M1, and its oligomerization, plays an important role to 
interact with HA, NA and M2, meanwhile keeps vRNP at the final step of closing 
and budding off of the viral particle. It was reported that M2 is the key player to 
alter membrane curvature at the neck of the budding virus, causing membrane 
scission and the release of the progeny virion (Rossman & Lamb, 2011). Finally, 
NA removes sialic acid residue from glycoproteins and glycolipids. The newly 
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made viral particle is then released from the plasma membrane for infection of 
new cells. 
 
2.3 Influenza Virus Epidemiology and Evolution 
2.3.1 Epidemiology of Influenza Viruses 
 Both type A and B influenza viruses are able to cause epidemics in 
humans. These infections can result in a spectrum of clinical disease in humans, 
ranging from mild to severe respiratory illness requiring hospitalization and 
medical treatment (Monto, 2008; Paul Glezen et al., 2013). ICV infects humans 
and is able to cause mild to severe illness in young children (Matsuzaki et al., 
2006). Pathogenesis of newly emerged IDV in humans is yet to be studied. 
 IAV is a serious public health concern because it causes severe illness 
and death in all ages, especially in high-risk populations. IAV is only influenza 
virus that causes worldwide influenza pandemics. The first pandemic of influenza 
was traced back to 1918 in Spain.  The notorious 1918 Spanish A/H1N1 virus 
killed approximately 50 million people. Since then, a few small-scale human 
influenza pandemics have occurred, respectively, in 1957 (A/H2N2), 1968 
(A/H3N2), 1977 (A/H1N1), and more recently the pandemic A/H1N1 “swine flu” in 
2009 (Belser & Tumpey, 2018). Worldwide, seasonal influenza epidemics result 
in millions cases of severe illness and about 290,000 to 650,000 respiratory 
deaths yearly (WHO, 2018). The primary reservoir of influenza A viruses (IAV) is 
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migratory waterfowl. However IAV have rapidly adapted to infect and transmit 
between a variety of avian and mammalian species. IAV also has a high level of 
diversity in terms of genetic differences. In contrast, influenza B viruses (IBV) and 
influenza C viruses (ICV) reside primarily in human host, although sporadically 
infections of other species have been reported (Nedland et al., 2018; Salem et al., 
2017).  Influenza D viruses (IDV) have recently emerged in swine and cattle 
populations in North America and Eurasia (Chiara et al., 2016; Collin et al., 2015; 
Ducatez et al., 2015; Hause et al., 2013; Luo et al., 2017; Shin et al., 2016; Zhai 
et al., 2017). Serological evidences of spillover IDV infections in humans, horses, 
and small ruminants have been reported (Hause et al., 2013; Nedland et al., 
2018; Quast et al., 2015; Salem et al., 2017). 
2.3.2 Evolution of IAV 
 The presence of genetically and antigenically distinct IAV subtypes of HA 
and NA allow for rapid viral evolution through the process of antigenic shift, which 
is defined as the emergence or reemergence of an influenza subtype in a naïve 
host population. There are two major mechanisms that enable IAV evolve and 
adapt to new host species: (i) the vRNA genome are segmented, therefore new 
strain can emerge through reassortment during co-infection of a cell with two or 
more strains; (ii) IAV polymerase complex is responsible for rapid but error-prone 
vRNA replication, producing variants of the viral proteins, including the HA and 
NA, that potentially cause antigenic or genetic drift (Miotto et al., 2010). IAVs 
were found in various vertebrate species, where they form reservoirs that do not 
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easily mix. While human IAVs do not spread in birds and vice versa, the species 
barrier to pigs is relatively low, so that pigs might function as "mixing vessels" for 
the creation of new pandemic reassortants (Nelson & Vincent, 2015). 
 Phylogenetic studies revealed that about 100 years ago, an avian 
influenza A virus had crossed the species barrier, presumably first to pigs, and 
from there to humans, forming the new stable human and classical swine 
lineages. In 1979, again, an avian virus showed up in the North European swine 
population, forming another stable swine lineage. The North European swine 
isolates from 1979 until about 1985 were genetically extremely unstable. A 
hypothesis is put forward stating that a mutator mutation is necessary to enable 
influenza virus to cross the species barrier by providing the new host with 
sufficient variants from which it can select the best fitting ones. As long as the 
mutator mutation is still present, such a virus should be able to cross the species 
barrier a second time, as happened about 100 years ago (Belser & Tumpey, 
2018). Although the most recent swine isolates from northern Germany are again 
genetically stable, nevertheless, we should be on the alert to watch whether a 
North European swine virus shows up in the human population in the near future. 
In 1998, a highly virulent H3N2 virus swept across North America.  Genetic 
analysis found that this virus was derived from avian, human and swine influenza 
viruses and was consequently called triple reassortant H3N2 swine influenza 
virus (Ma et al., 2010; Ma et al., 2014).  In the following two decades, emerging 
new HA and NA genes, and triple reassortant gene constellation (TRIG) from this 
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triple reassortant SIV have synergistically resulted in a rapid explosion of 
genetically diverse SIVs (Ma et al., 2010; Ma et al., 2014). 
2.3.3 Interspecies transmission of IAV 
 
Figure 3. Interspecies transmission of influenza A viruses 
Reservoirs and inter-species transmission events of low pathogenic avian influenza 
viruses. Wild birds, domestic birds, pigs, horses, humans and bats maintain their own 
influenza A viruses (arrow in circle, subtype in bold). Spill-over events occur occasionally, 
most frequently from wild birds (arrow straight, subtype normal font). (Short et al., 2015) 
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 Interspecies transmission of a virus can lead to a change in the host 
tropism of the virus. The change may involve multiple factors. The HA has long 
been considered to be the primary determinant of influenza virus host range 
determinant. HA binds to cellular glycosylated receptor proteins via their terminal 
sialic acid residues. Mutations in the HA may change the receptor-binding 
specificity of the IAV and lead to the interspecies transmission. Humans possess 
sialic acid bound to galactose in an α2,6 orientation whereas avian receptor 
proteins possess α2,3 oriented sialic acid-galactose linkages (Short et al., 2015).  
Swine possess both α2,6- and α2,3- linked sialic acids, leading to their 
designation as “mixing vessels” for influenza viruses.  On the other hand, the 
diversity of cellular receptors in various species is thought to be a determinant 
factor of influenza virus tropism.  IBV binds sialic acids linked to galactose in 
either α2,6 or α2,3 orientation (Vijaykrishna et al., 2015).  In contrast to IAV and 
IBV, ICV and IDV bind to 9-O-acetylated sialic acids (Song et al., 2016; Wang & 
Veit, 2016). 
 The primary reservoir for IAV is waterfowl (Figure 3). The virus replicates 
primarily in gut tissues in these birds but rarely causes disease.  Low level of 
genetic mutation rate and low pathology in waterfowl infected with IAV suggest 
that IAV has reached evolutionary stasis in these species. Sixteen HA (HA1-16) 
and nine NA (NA1-9) subtypes are found in aquatic avian species, however a 
recent study characterizing an IAV from bats in Central America found novel HA 
and NA subtypes (Joseph et al., 2017).  IAV also infect a wide variety of 
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mammals but host susceptibility is usually limited to relatively few HA and NA 
subtypes (Figure 3) (Joseph et al., 2017; Short et al., 2015).  
 Unlike IBV and ICV that rarely transmit across species, sustained inter 
species transmission of IAV has been demonstrated (Joseph et al., 2017; Short et 
al., 2015). IAV are unique among the Orthomyxoviridae in that they possess 
numerous subtypes that co-circulate. This allows for rapid antigenic shift, resulted 
by co-infection and reassortment of multiple IAV strains from different subtypes. 
Reassortment is frequently seen in SIV. There are numerous subtypes and 
lineages of IAV co-circulating in pigs (Palese & Wang, 2011). From the first 
isolation of swine influenza virus in 1930 until 1998, there was very little diversity 
in SIV. H1N1 viruses dominated swine influenza until the 1990’s when H3N2 
viruses also became prominent (Vincent et al., 2008).  In 1998, a triple 
reassortant H3N2 virus consisting of avian, human and swine influenza virus 
segments was identified in pigs that was associated with severe clinical disease 
(Olson & Dinerstein, 2002). The triple reassortment gene constellation (TRIG) 
was rapidly disseminated through the North American swineherd, replacing the 
previous wholly-swine influenza viruses. The 2009 pdmH1N1 was another 
example of reassortment related to SIV. These changed strains have 
successfully crossed tropism barriers and become endemic to new host 
populations. 
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2.4 Host Immunity and Immune Evasion of Influenza Viruses 
 Upon detection of IAV infection, host immune system is activated to 
defend against the viral infection. Innate immune response is the first line of 
defense against viral infection. The adaptive immunity, mediated by B cells and T 
cells, will recognize, fight and eliminate pathogens. On the other hand, IAVs have 
utilized multiple ways to escape from host immunity. 
2.4.1 Innate immunity against IAV infection 
 Innate immunity is the first line of defense against pathogens. During the 
IAV infection, the conserved components called pathogen associated molecular 
patterns (PAMPs) are recognized by host pathogen recognition receptors 
(PRRs). These PAMPs have certain characteristic of viral RNA that are not 
shared by cellular RNAs, such as regions of double-stranded RNA (dsRNA) or 
the presence of a 5’-triphosphate group. Retinoic acid-inducible gene-I protein 
(RIG-I) and toll-like receptor (TLR) are well-known PRRs for IAV (Gack, 2014; 
Lee et al., 2013).  The activation of the signaling pathways induces the 
production of various cytokines and antiviral molecules.  
 RIG-I like receptors (RIG-I, MDA5, and LGP2) are characterized by a 
conserved domain structure, consisting of a central DExD/H-box helicase domain 
and a C-terminal domain (CTD), both of which are responsible for binding viral 
RNA.  The RIG-I like receptors (RLRs) recognizes the intracellular non-self 
ssRNA and transcriptional intermediates of IAVs in the infected host cells. 
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Following the recognition of PAMPs, RLR is activated and its caspase activation 
and recruitment domain (CARD) is modified. This triggers the downstream 
transduction signaling at the outer mitochondrial membrane (Gack, 2014). 
Subsequently, downstream signaling pathways are activated, leading to type I 
IFN gene expression (Gack, 2014).  
 Toll‐like receptors (TLRs) are pattern recognition receptors expressed by 
the antigen‐presenting dendritic cells, monocytes/macrophages, and epithelial 
cells, which trigger the innate immune responses against invading pathogens 
(Lee et al., 2013). The endosomal TLRs can detect viral nucleic acids (dsRNA, 
ssRNA, CpG oligodeoxynucleotides). Recent in vitro and in vivo studies on 
influenza pathogenesis have shown that TLR activation induces expression of 
type I interferon and pro‐inflammatory cytokines (e.g., IL‐6, TNF‐α), thereby 
limiting viral replication and dissemination, mediating tissue inflammation. These 
cytokines will facilitate the development and maturation of adaptive immunity. 
Animal studies showed that TLR ligands may rapidly up regulate the innate 
immunity to provide broad‐range, virus strain non‐specific protection against 
lethal influenza challenge (Lee et al., 2013). 
2.4.2 Adaptive immunity against IAV infection 
 The second line of defense against infection is the adaptive immune 
response, which consists of humoral and cellular immunity. Adaptive immunity is 
relatively slow but specific upon the first time infection. The formation of 
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immunological memory of the adaptive immunity enables faster and stronger 
response after a second infection with the same pathogen.  
2.4.2.1 Humoral immunity 
 IAV infection induces the production of IAV-specific antibodies by B cells. 
Antibodies react to the HA and NA largely correlate with protective immunity. 
Antibodies binding to the receptor-binding site on the trimeric globular head 
region of HA can confer neutralizing immunity to IAV infection. The neutralizing 
antibodies can block virus attachment to host cells and subsequently block 
receptor-mediated endocytosis (Air, 2015). However, the HA globular head (see 
section 2.5 below) is highly variable, as a result, most antibodies directed against 
HA are influenza virus strain-specific and fail to neutralize antigen drift variants 
and viruses of other subtypes (Yu et al., 2008). Humoral immunity provides long-
lasting antibody mediated protection against the strains that antigenetically 
resemble the infected strain. Of interest, broadly reacting antibodies directed 
against the conserved stem region of HA have been identified (Wang et al., 
2010b; Wang et al., 2010c). 
 Antibodies react to sialydase NA, which release budding virus from 
infected cells, also exert protective immunity. Although NA-specific antibodies are 
not neutralizing, i.e. not able to block virus entry and fusion, they are still able to 
inhibit the enzymatic activity of NA and therefore limit the viral spread and reduce 
virus replication efficiency (Marcelin et al., 2012). In addition, transmembrane 
protein M2 plays an important role in uncoating the viral genome in the 
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endosome. Protective effect of M2-specific antibodies was demonstrated in 
recent studies (Kim et al., 2017; Rappazzo et al., 2016). Furthermore, evidences 
indicate that NA-, M2- and NP-specific antibodies may contribute to ADCC 
(Vanderven et al., 2017). Since M2 and NP proteins are highly conserved 
between various influenza A virus subtypes, the antibodies may confer clearance 
to heterosubtype viruses, although their mechanisms of actions are poorly 
understood (Vanderven et al., 2017). In addition to serum antibodies, local 
mucosal IgA antibodies are important to protect airway epithelial cells from 
infection (Rahn et al., 2015). 
2.4.2.2 Cellular immunity 
 Primary T-cell responses are induced when naive T-cells encounter 
antigen presented via MHC I or MHC II molecules. During IAV infection, viral 
proteins degraded into peptides (8–10 amino acids) that were loaded onto the 
HLA molecules and presented to circulating T-cells (Leone et al., 2013). The 
presented antigens activate the naive T-cell, which as a result leads to the 
proliferation and differentiation of naive T-cells into effector and memory T-cells. 
The IAV-specific CD8+ cytotoxic T cells (CTLs) can recognize and eliminate IAV-
infected cells through cytokine-directed killing or Fas-FasL mediated killing, thus 
preventing the spreading of virus. IAV-specific CD8+ CTL cells predominantly 
recognize internal proteins represented by M1 and NP (Jameson et al., 1998). 
CD8+ T cells can be classified as Tc2, Tc17, Tc9, and CD8+ Treg cells, in 
addition to CTLs. CTL, Tc2 and CD8+ Treg cells have a strong cytotoxic function, 
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which is in contrast to Tc9 and Tc17 cells with a low cytotoxic function (Huber & 
Lohoff, 2015). However, Tc17 cells were demonstrated to provide protection to 
influenza virus infection (Hamada et al., 2009). CD4+ T-cells have been 
demonstrated to directly kill virally infected cells (Topham & Doherty, 1998). In 
addition, CD4+ T-cells can provide help to CD8+T-cells. CD4+ T cells also play 
an important role in humoral immunity (Jameson et al., 1998). After IAV infection, 
variant IAV-specific memory T-cell populations are established that may enable 
the host adaptive immune system rapidly respond to future infection (Jameson et 
al., 1998).  
2.4.3. Escape of innate and adaptive immunity 
 IAV adopts various strategies to evade immunity. Binding of influenza viral 
proteins to various components of the innate immune system leads to their 
inhibition. Firstly, the NS1 protein is the major player to antagonize the antiviral 
innate immune response. NS1 inhibits RIG-I receptor signaling by various 
means. It blocks transcriptional activation of the IFN-β promoter (van de Sandt et 
al., 2012). Other than NS1, PB2 and PB1-F2 can reduce the IFN-β induction. 
Viral polymerase complex, consisting of PB2, PB1 and PA, is also involved in 
cap-snatching of host mRNAs and thereby reduces host cell gene expression 
including that of IFN-β.  The encapsidation of vRNA by NP proteins is likely to 
reduce the formation of dsRNA, which could otherwise lead to activation of RIG-1 
signaling (van de Sandt et al., 2012).  
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 A combination of immune pressure in the human population and the high 
mutation rate of the influenza A virus leads to new IAVs that can escape the 
existing adaptive humoral and cellular immune responses. Due to the lack of 
proofreading activity, the transcription of viral RNA by the viral RNA polymerase 
is error prone and results in nucleotide changes and amino acid changes, that 
can reduce effectiveness of recognition of antibody as well as CTL epitopes. 
Antigen shift is another mechanism IAV use to escape humoral immunity and 
CTL responses (Johnson et al., 2017; Shao et al., 2017). 
 
2.5 Influenza hemagglutinin structure biology and Universal Vaccine  
2.5.1 Receptor binding specificity of HA (HEF) and host tropism 
 HA homotrimer forms spikes on the viral envelope. These spikes of HA 
bind to sialic acid on the surface of the host cell’s membrane. The HA precursor, 
HA0, is made up of two subunits: HA1, which contains the receptor binding 
domain, and HA2, which contains the fusion peptide. The detailed structure and 
function of HA protein has been described in detailed in Chapter 4 below. Two 
major linkages are found between sialic acids and the glycan to which they are 
bound: α2,3 and α2,6. These are extremely important for the specificity of the HA 
molecules in binding to cell surface sialic acid receptors found in different 
species. Viruses from humans recognize the α2,6 linkage, whereas those from 
avian and equine recognize the α2,3 linkages. Those from swine recognize both. 
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This explains the importance of swine being a good mixing vessel for avian and 
human influenza viruses, hence producing dangerous pathogenic viruses (Samji, 
2009). Interestingly, functionally important and conserved sequences in HA, such 
as the fusion peptide, are buried inside and not accessible for antibody 
recognition. HA2 stem domain is also relatively conserved when compared to 
HA1 globular receptor binding domain. These conserved domains or regions in 
the HA2 are good target for vaccine development toward a universal protection.   
2.5.2  Current IAV Vaccines 
 Currently most used seasonal influenza vaccines are egg-based, 
inactivated vaccines. More recently, FDA also approved cell-based vaccines and 
recombinant vaccines. Both trivalent and quadrivalent vaccines are made to 
increase the protection range (FDA, 2018). The IAV strains are selected 
according to recent epidemics. Although these vaccines are considered safe and 
efficacious, which are closely matched to circulating strains, infamous antigenic 
drift of influenza viruses under natural evolution or through egg culture enable the 
viruses to escape the neutralizing activity of antibodies induced by vaccination. 
Another issue is that the current vaccines usually fail to provide long-term 
protection and therefore require annual administration. Finally, in the event of a 
pandemic outbreak, the time consuming production of a new pandemic influenza 
vaccine is another concern. Seasonal influenza vaccines do not offer good 
protection against pandemic strains of novel subtypes due to the mismatch of 
humoral and cellular immune responses.  
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2.5.3  Universal IAV vaccine 
 One target of universal IAV vaccine is M2 protein. A number of vaccine 
studies using the extracellular domain of M2 (M2e) as an immunogen have 
demonstrated that M2e vaccines can offer protection against lethal challenge by 
some different subtypes in mice and ferrets. These M2e vaccines reduced viral 
shedding in the lower respiratory tracts of these animals (Deng et al., 2015). The 
protection against lethal challenge in mice could also be achieved by passive 
transfer with monkey sera containing high M2e antibody titers (Deng et al., 
2015). Human clinical trials for testing M2e vaccine efficacy are currently being 
conducted (Schotsaert et al., 2009). M2e-specific antibody enhancement in pigs 
may suggest that caution should be exercised when using M2e vaccination in 
humans. Please note that efforts toward exploring viral fusion machinery as a 
universal vaccine target has been described in Chapter 4 below.  
2.5.4 IAV Reverse Genetics and vaccine development  
 Over the past several decades, one most important progress in influenza 
research field is the development of numerous robust reverse genetics systems. 
With this system, researchers around the globe can study functions of encoded 
viral proteins and non-coding elements of viral genomes. Also various forms of 
influenza vaccines have been developed due to influenza reverse genetics 
system (Nogales & Martinez-Sobrido, 2016). Influenza virus contains segmented 
RNA genomes in a negative sense. So conversion of these unstable RNA into 
stable DNA through RT-PCR and placing them in the context of both polymerase 
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I and II promoters so both vRNA and mRNA molecules corresponding each 
individual can be generated, which is the technical foundation of influenza 
reverse genetics system.  This dissertation especially in Chapter 4 has 
harnessed influenza reverse genetics system to study structure-function of the B-
loop and CD helix. A reverse genetics recovered attenuated virus has been 
advanced to a pilot trial in pigs to evaluate its vaccine efficacy against both H1N1 
and H3N2 subtypes.    
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CHAPTER 3. DETAILED MAPPING OF THE LINEAR B CELL EPITOPES OF 
THE HEMAGGLUTININ (HA) PROTEIN OF INFLUENZA H1N1PDM09 VIRUS 
BY USING SYNTHETIC PEPTIDE ARRAY APPROACH 
 
3.0  Abstract 
 We presented here a detailed analysis of the antigenic determinants of the 
Hemagglutinin (HA) protein of pdm09 strain (subtype H1N1) by the HA peptide 
array in Enzyme-linked immunosorbent assay (ELISA) with immune serum from 
experimental infected pigs by swine influenza A viruses (SIVs). The peptide array 
contains 139 peptides spanning the HA protein of H1N1pdm09 and peptides are 
14- or 15-mers with 11 amino acid overlaps. A panel of swine antisera against 
SIV H1 clusters α, β, γ, δ-A, δ-B, H1N1pdm09, and H3 cluster was used in this 
study and SIVs used for swine hyperimmune sera production are representative 
subtypes and clusters of SIV circulating in North America. The results of these 
studies identified three immunedominant peptides, one located in the HA1 
(amino acids 57-71) and two in the HA2 (amino acids 481-495, and 553-566), 
reactive to its homologous antisera (H1N1pdm09). Analysis of peptide reactivity 
with heterologous serum samples revealed that antibody responses to two HA2 
peptides (amino acids 481-495 and 553-566) are completely conserved among 
antisera of all H1 clusters. In addition to H1N1pdm09, HA1 peptide (amino acids 
57-71) was reactive to SIV H1 γ antisera. Interestingly, none of peptides in HA 
peptide array of H1N1pdm09 were reactive to SIV H3 antisera, despite that this 
antisera has a HI antibody titer similar to those of H1 clusters antisera. Structural 
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modeling localized two conserved immunodominant determinants to the 
membrane proximal external region (MPER) (amino acids 481-495) and the 
intracytoplasmic tail (amino acids 553-566) of the HA molecule. Finally, 
intranasal inoculation of peptides 15 and 121 into pigs revealed that peptide 121, 
not peptide 15, was able to generate antibody responses in some animals. These 
antigenic analyses provide an important foundation for further analyzing the 
immune response against these peptides during natural SIV infections and also 
provide potential peptide substrates for diagnostic assays and for vaccine 
strategies. 
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3.1 Introduction 
 Swine influenza is caused by swine influenza A virus (SIV), which belongs 
to the Orthomyxoviridae family (Easterday, 1980). The pathogen is an important 
component of the porcine respiratory disease complex and by itself can have a 
significant impact in the swine industry (Vincent et al., 2008). An additional 
concern regarding SIV, is its zoonotic potential, as under certain circumstances, 
it can be transmitted to humans, which is best exemplified by 2009 H1N1 
pandemic originated from swine source (Maines et al., 2009).  Recently, 
transmissions of variant swine H3N2 virus (H3N2v) to humans have also been 
documented (Wong et al., 2013).   
 A typical outbreak of respiratory disease caused by SIV is characterized 
by sudden onset, and rapid spread within a herd. Clinical symptoms associated 
with swine influenza may include coughing, sneezing, nasal discharge, elevated 
rectal temperature, lethargy, breathing difficulty, and depressed appetite 
(Easterday, 1980; Vincent et al., 2008). While morbidity rates may reach 100% 
with SIV infections, mortality rates are generally low.  
 The genome of SIV is separated into 8 independently RNA segments at 
the negative-sense that allows for frequent reassortment when two different 
viruses infect and replicate within the same cell of a pig. Reassortment event 
often results in the production of new influenza virus (antigenic shift), which 
renders the current strain-specific vaccine strategy ineffective.  In addition, 
influenza A virus has the unique capacity to undergo genetic variations (antigenic 
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drift) by being able to mutate up to 50% of the amino acid sequence of its major 
surface protein, hemagglutinin (HA), without changing the function of the HA. 
Both antigenic drift and antigenic shift contribute to apparent failures of swine 
influenza vaccines when used in swine industry.   
 In the United States, SIV H1N1, H1N2, and H3N2 subtypes have emerged 
as the major causes of swine influenza, although two other subtypes of SIV 
(H3N1 and H2N3) have also been isolated from the diseased pigs on some 
occasions (Rajao et al., 2018). Each subtype consists of numerous lineages or 
clades and these lineages of swine influenza virus circulate concurrently in pigs, 
which present a challenge to effective control and prevent of this important 
disease (Rajao et al., 2018). 
 The aim of this study was to determine the antigenic determinants of the 
hemagglutinin (HA) protein of swine H1N1 pandemic 2009 virus (H1N1 
pdm09) by using the HA peptide array in Enzyme-linked immunosorbent assay 
coupled with immune serum from experimental infected pigs by SIVs. The 
peptide array contains 139 peptides spanning the HA protein of H1N1pdm09 and 
peptides are 14- or 15-mers with 11 amino acid overlaps. A panel of swine 
antisera against SIV H1 clusters α, β, γ, δ-A, δ-B, H1N1pdm09, and H3 cluster 
were used in this study (Hause et al., 2010; Lorusso et al., 2011). Our 
experiments identified two conserved peptide antigens (peptides 121 and 139) 
located in HA2 that were reactive to all tested SIV H1 antisera. In addition, 
peptide 15 in HA1 was recognized by a subset of H1 antisera. Interestingly, none 
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of these identified peptides were recognized by SIV H3 reference antisera. The 
results of our experiments shall provide an important foundation for further 
analyzing the immune response against these peptides during natural SIV 
infections and also provide potential peptide substrates for design of diagnostic 
assays and vaccine strategies against influenza A virus infection of swine. 
 
3.2  Materials and Methods 
3.2.1  Peptide array  
 Peptide array is derived from the hemagglutinin (HA) protein of Influenza 
Virus A/California/04/2009 (H1N1)pdm09 with swine origin, which was obtained 
through BEI Resources, NIAID, NIH (Cat# NR-15433). This is a 139-peptide 
array that spans the whole HA protein. Peptides are 14- to 15-mers, with 11 
amino acid overlaps. Each peptide was dissolved with Dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich) at a concentration of 1 mg/ml.    
3.2.2  Pig sera.  
 A previously described standard panel of porcine immune sera collected 
from experimentally inoculated pigs was used in this study (Hause et al., 2010). 
Three-week-old SIV-negative pigs were obtained from a commercial vendor.  
Groups of 3 pigs were used for antisera generation against a panel of swine 
influenza virus reference isolates, including H1 clusters (α, β, γ, δ-A, δ-B, 
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H1N1pdm09) and a H3 cluster. Each of these viruses was propagated in ST cells 
(reaching to 1280 to 2560 hemagglutination units per ml) followed by the 
inactivation with 5 mM binary ethyleneimine (BEI) (Sigma-Aldrich) for 24 hours at 
37ºC. After formulation with Trigen, a proprietary adjuvant (Newport Laboratories, 
Worthington, Minnesota), each of these viral antigens was inoculated into a 
group of three pigs (2 ml each pig) on days 0, 7, 14, and 21 intramuscularly. Sera 
were collected and pooled on days 0 and 35, respectively, prior to testing.  
Because sera collected from inoculated pigs had very high HI titers (homologous 
HI 1280 to > 20,480), sera were diluted four-fold to 16-fold in serum collected 
from cesarean-derived, colostrum-deprived pigs to achieve homologous HI titers 
of 1280. The diluted reference antisera stocks were aliquoted and frozen at -
80ºC. In addition, we generated negative control sera by injecting pigs with ST 
cell debris and adjuvant. Sera generated from the ST cell debris were not diluted. 
No immune pig sera obtained from 50 pigs known to be free from swine influenza 
exposure and infection (negative for IAV-specific by ELISA were used as 
negative control sera to detect background immunoglobulin binding in peptide 
ELISAs. 
3.2.3  Peptide ELISA.  
 Flat bottom 96-well plates were coated with each of the synthetic HA 
peptides (100 μl/ 0.5μg each well) in coating buffer (10 mM NaHCO3 buffer, pH 
9.6) for overnight incubation at 4°C. After washing five times (300 μl/well) with 
PBST wash buffer (PBS with Tween 20), plates were blocked with blocking buffer 
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(PBST containing 0.2% gelatin) for 2 hours at 37°C followed by additional 
washing.  Then 100 μl of diluted serum samples (1:300 in PBST containing 
0.01% gelatin) was added to each well and incubated at 37°C for 1 hour. 
Following five times washing, antibody binding was detected by incubation with 
100 µL of goat anti-swine IgG-HRP conjugates (SeraCare) diluted 1∶2000 in 
blocking buffer at 37°C for 30 min. The calorimetric reaction, indicative of the 
presence of bound antibody, was mediated by the addition of 100 µL freshly 
prepared tetramethylbenzidine (TMB) substrate solution (SeraCare). The 
reaction was stopped by addition of 50 µL of 4 M sulfuric acid and the optical 
density (OD) was measured at 450 nm in an ELISA microplate reader (BioTek). 
 The 50 negative control sera coupled with randomly selected 4 peptide 
pools (each peptide pool consisting of five sequentially overlapping peptides) 
were used to determine the cut-off value of the peptide ELISA, which was equal 
to the mean OD of the negative samples plus 3 standard deviations. The derived 
positive cut-off value of 0.18 or greater was used to determine whether a given 
SIV cluster-specific serum had positive serological reactivity to the peptides. To 
reduce the background (BG) noise reaction caused by the hydrophobic binding of 
immunoglobulin and immune-complexes in pig sera to plastic surfaces, all the 
OD values obtained in peptide(s)-coated wells were subtracted from the BG OD 
values in peptide(s)-uncoated wells.    
3.2.4 Hemagglutination inhibition (HI) assay.  
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 HI assays were performed following standard procedures (Hause et al., 
2012). In brief, sera were treated with a receptor-destroying enzyme for 24 h at 
37°C and then adsorbed with a 20% suspension of turkey erythrocytes in 
phosphate-buffered saline (PBS) for 30 min at room temperature. Virus 
suspensions containing 4 to 8 HA units of virus were incubated for 1 h with serial 
2-fold dilutions of antiserum, and the HI titer was determined as the reciprocal of 
the highest dilution that showed complete inhibition of hemagglutination using 
0.5% washed turkey erythrocytes.  
3.2.5 Virus neutralization assay.  
 Virus neutralization assays were performed as previously described (Ran 
et al., 2015), with slight modifications. Two-fold serial dilutions in PBS, from 1:4 
to 1:32,768, were performed on the sera. Next, 100 μl of 40 to 200 median tissue 
culture infective doses (TCID50)/100 μl of virus was added to each serum dilution 
and incubated for 1 h at 37°C in 5% CO2. The serum-virus mixture was next 
transferred to a confluent monolayer of MDCK cells and incubated at 37°C in 5% 
CO2 for 4 days. Viral neutralization was assessed by a lack of cytopathic effects 
in each well by microscopy. Back titrations were performed on MDCK cells to 
confirm a virus concentration of 40 to 200 TCID50/100 μl. 
3.2.6 Structural locations of peptides tested positive in ELISA.  
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 The Hemagglutinin structure (PDB 3LZG) from H1N1 pdm09 that derives 
the HA peptide array was chosen as the template to locate ELISA-positive 
peptides in the context of the HA structure.  
 
3.2.7 Sequence logos.  
 We used pLogo software (http://rth.dk/resources/plogo/) to determine the 
sequence conservation of the identified B-cell linear epitopes.  For this purpose, 
we analyzed all available SIV cluster-specific full-length HA protein sequences of 
swine influenza A virus strains that circulated between 2006 to 2015 in pigs 
farms of the United States.   Sequence logo provides better description of 
sequence conservation than consensus sequences and can reveal significantly 
structural and functional features of the identified epitopes. Each logo consists of 
stacks of letters (amino acids), one stack for each position in the sequence. The 
overall height of each stack indicates the sequence conservation at that position 
(measured in bits), whereas the height of symbols within the stack reflects the 
relative frequency of the corresponding amino acid at that position. The residue 
position in the block is shown on the X-axis, and the information content is shown 
on the Y-axis. The default color scheme displaying different amino acids 
according to their different chemical properties is as follows: polar amino acids 
(G, S, T, Y, C, Q, N) colored with green, basic (K, R, H) with blue, acidic (D, E) 
with red, and hydrophobic (A, V, L, I, P, W, F, M) amino acids with black.  
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3.2.8 In vivo evaluation of immunogenicity of peptides 15 and 121.   
 3-week-old commercial influenza antibody-negative pigs were obtained 
from a commercial vendor in Minnesota. The pigs were acclimatized for 7 days 
before inoculation of peptide immunogens. Maintenance of pigs and all 
experimental procedures were conducted in accordance with the guidelines of 
the Institutional Laboratory Animal Care and Use Committee, South Dakota State 
University. Peptide antigens were conjugated with carrier protein KLH (500µg of 
peptide dissolved in total volume of 1ml PBS). Each of six 4-week-old influenza 
antibody-negative commercial pigs were inoculated intranasally with one ml 
suspension of the KLH-conjugated peptide 15 and 121 along with heat labile 
enterotoxin (25 µg LT), while each of 4 control pigs received 1 ml PBS each 
intranasally. Two weeks later, all piglets received a booster dosage. Blood 
samples were collected for the serum isolation via the jugular vein from piglets 2 
weeks after the second round of immunization. Serum samples were also 
obtained by the same method prior to immunization. Peptide-specific antibodies 
were measured in the ELISA assay as described above.   
 
3.3  Results  
3.3.1 Identification of HA peptide pools reactive to SIV H1N1pdm09 reference 
serum.  
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 To localize linear B-cell epitopes of the hemagglutinin (HA) protein of 
H1N1 pdm09 in swine, the pig H1N1pdm09 serum was reacted against the 
peptide array derived H1N1 pdm09 and analyzed for specific antibody binding. 
We first screened antibody reactivity against peptide pools in the ELISA and 
each peptide contained five sequentially overlapping peptides that were arranged 
from the N-terminal end of the HA protein. Three out of the twenty-eight peptide 
pools were tested positively against H1N1pdm09 antisera (Figure 4).  
Table 3. Summary of positive peptide pools identified in ELISA using swine 
antisera against H1N1 pdm09 virus. 
 
Note: “-” sign indicates that peptide pools are not reactive to swine antisera 
raised against homologous H1N1 pdm09 virus (i.e., OD values less than the 
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ELISA cut-off 0.18). Positive peptide pools are indicated with red font color. 
Sequences with yellow shades are located in HA1. Sequences with blue shades 
are located in HA2. Junction sequence between HA1 and HA2 are not shaded. 
Reported OD data represent average background-corrected OD values obtained 
from three independent experiments, each assayed in duplicate. See Materials 
and methods section for details. 
 
3.3.2 Identification of individual peptides recognized by SIV H1N1pdm09 
reference serum.  
 To further determine individual peptide epitopes from the above positive 
peptide pools, each peptide was tested against H1N1pdm09 antisera in the 
peptide ELISA under similar experimental conditions. The reactivity pattern was 
as follow: peptide 15 from the positive peptide pool 11-15 reacted strongly with 
antisera; similarly, peptide 121 from the positive peptide pool 121-125 was 
recognized by H1N1pdm 09 antisera; interestingly, three overlapping peptides 
137, 138, and 139 all reacted with antisera. Significantly, the observation of an 
immunodominant porcine B cell epitope represented by peptide 15 is in 
agreement with an early study demonstrating that this peptide was 
immunoreactive against convalescent sera from H1N1pdm09 patients (Zhao et 
al., 2011). Porcine B cell epitopes represented by peptides 121, 137, 138, and 
139 have not reported previously in the context of human infection by 
H1N1pdm09 virus.  
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Table 4. Individual peptides reactive to swine antisera against H1N1 pdm09 
virus 
Peptide OD  Sequence 
15 0.662   57  KLCKLRGVAPLHLGK 71 
121 0.262   481 CFEFYHKCDNTCMES 495 
137 1.101   545 VSLGAISFWMCSNGS 559 
138 1.426   549 AISFWMCSNGSLQCR 563 
139 0.636   553 WMCSNGSLQCRICI 566 
Note: The underlined amino acid residues for peptides 137, 138, and 139 are 
those shared among three reactive peptides. Reported OD data represent 
average background-corrected OD values obtained from three independent 
experiments, each assayed in duplicate. See Materials and methods section for 
details. 
3.3.3 Structural locations of positive peptides.   
 Peptide 15 (residues 57 to 71) is located in the HA1 subunit, while peptide 
121 (residues 481 to 495) is located in the HA2 region. These two peptides are in 
the HA ectodomain. In contrast, peptides 137 (residues 545 to 559), 138 
(residues 549 to 563), and 139 (residues 553 to 566) are within the 
transmembrane (TM) domain and cytoplasmic tail of HA.  To visualize the 
location of the peptides on the HA protein, we mapped the peptides on the 
resolved pdm09 HA’s ectodomain structure (Fig. 4). Peptide 15 comprises of a 
mixture of loop and ß–sheet conformations, which links the stem and the globular 
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domains and is largely surface exposed. Peptide 121 containing a mixture of α-
helix, loop, and ß–sheet is located in close proximity to the transmembrane 
region with the helical region fully exposed to the surface. The surface-exposed 
nature of peptides 15 and 121 may make their corresponding antibodies bind to 
the virions so antibody binding may have an effect on viral replication. 
Visualization of three other peptides (peptides 137, 138, and 139) could not been 
performed due to the unavailable structure of HA’s transmembrane region and 
cytoplasmic tail. 
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Figure 4. Locations of reactive peptides in the context of the hemagglutinin 
(HA) structure (PDB 3LZG) of H1N1 pdm09 virus.  
The Hemagglutinin structure (PDB 3LZG) from H1N1 pdm09 that derives the HA 
peptide array was chosen as the template to locate ELISA-positive peptides in 
the context of the HA structure. Peptides 15 and 121 are colored with light green 
and dark blue, respectively.    
Pep15 
Pep121 
HA1 
HA2 
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3.3.4 Cross reactivity of peptides to reference sera representing different H1 
clusters/subtypes of SIV.  
 We next determined whether pig reference sera, representative of 
different H1 clusters and H3 subtype of SIV, recognized the identified peptides. 
For this experiment, we focused on peptides 15, 121, and 139.  Peptides 137 
and 138 were not further evaluated because peptide 139 significantly overlaps 
with peptides 137/138 and peptide 139-derived data may be viewed as a 
representative of these three overlapping peptides. In addition, all reference sera 
used in this study were uniformly diluted into same HAI antibody titer 1:1280 
against the virus that was used to generate these sera. Figure 5 summarizes the 
serological cross-reactivity of these peptides. Peptide 139 was highly reactive to 
all tested SIV H1 antisera, while peptide 121 was moderately reactive to all these 
sera. The strong relative inter-cluster reactivity (immunodominant) demonstrated 
with peptide 139 and the weak cross-reactivity (immunoreactive) noted with 
peptide 121 concurs with the results obtained with the reference pdm09 serum 
(Tables 3 and 4). Furthermore, in addition to H1N1 pdm09 reference serum, 
peptide 15 was weakly reactive to H1 γ serum. Significantly, none of these three 
peptides were recognized by SIV H3 antisera, despite that this serum has a HAI 
antibody titer similar to those of H1 clusters antisera. Three peptides displayed 
no antibody binding activity with the reference SIV antibody serum.  
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Figure 5. Recognition of three positive peptides by swine antisera raised 
against different clusters of swine H1N1 and a H3N2 subtype. 
Each of three peptides (15. 121, and 139) was used to coat 96-well plate. Swine 
antisera (1:300) from indicated H1 and H3 clusters of swine influenza were 
examined for the presence of antibodies to these three peptides using ELISA as 
detailed in materials and methods section. The background-corrected OD values 
of antisera for each peptide are calculated and plotted. The data presented in this 
figure are representative of three independent experiments, each assayed in 
duplicate.  
3.3.5 Conservation analysis of the identified linear peptide epitopes in different 
H1 clusters and H3 subtype of swine influenza A viruses.  
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 We used sequence logos (O'Shea et al., 2013) to visualize the 
conservation of individual amino acids within each identified epitope, with the 
height of each letter indicating the proportion of sequences that contain the 
residue at that site (Figure 6). Sequence of peptide 139 (WMCSNGSLQCRICI) is 
completely identical among all H1 clusters except for δ-B (Delta2) cluster. The 
vast majority (90%) of Delta2 strains have an arginine (R) at position 563 (R563), 
which is akin to SIV H1 strains in other clusters, while another 10% have a 
closely related lysine substitution (K563). This substitution seems not affecting 
the recognition of peptide 139 by Delta2 antisera. In contrast, 6 positions in the 
corresponding amino acid sequences of SIV H3 strains are occupied by different 
amino acids. Epitope conservation analysis of peptide 139 supports its universal 
recognition by all tested H1 cluster serum, not by a H3 subtype sera. Peptide 121 
(CFEFYHKCDNTCMES) is highly conserved among all H1 clusters. Amino acid 
variations in this epitope are centered on positions 489, 490, and 491. For 
example, all strains of cluster alpha have an alanine (A) at position 491, while all 
strains of Beta and 99% of Gamma strains have a closely related threonine 
substitution (T491). Interestingly, Glutamic acid (E) occupies this position at 
Delat1 and Delat2 strains. Changes at these three positions have no substantial 
effects on the universal recognition of peptide 121 by antiserum of H1 clusters. 
Analysis also showed that SIV H3 strains differed from H1 strains by 8 positions 
in the corresponding region and this significant variation in the epitope may 
explain why peptide 121 is not recognized by SIV H3 antisera.  Analysis of the 
sequence similarity in peptide 15 (KLCKLRGVAPLHLGK) displayed by various 
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H1 clusters also supported a relation between epitope sequence conservation 
and antibody recognition.  In addition to homologous sera (pdm09 H1N1), 
antisera generated against Gamma cluster (pdm09 belongs to this cluster) also 
recognized peptide 15. P15 peptide sequence is completely conserved among all 
analyzed strains of Gamma cluster. Interestingly, antiserum generated against 
other clusters of SIV subtype H1 and a H3 subtype strain failed to be reactive to 
this epitope due to multiple changes in the region.   
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Figure 6. Conservation of identified peptide epitopes among swine 
influenza A H1N1 and H3N2 viruses. 
Logo analysis is shown for the frequency of each amino acids within each of 
three peptides in swine influenza strains from indicated H1 clusters and H3 that 
circulated between 2006 to 2015 in pigs farms of the United States. The height of 
the letter indicates the frequency of individual amino acid residue at that site. The 
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residue position in the block is shown on the X-axis, and the information content 
is shown on the Y-axis. The default color scheme displaying different amino 
acids according to their different chemical properties is as follows: polar amino 
acids (G, S, T, Y, C, Q, N) colored with green, basic (K, R, H) with blue, acidic 
(D, E) with red, and hydrophobic (A, V, L, I, P, W, F, M) amino acids with black. 
3.3.6 Evaluation of immunogenicity of peptides 15 and 121 in pigs.  
 We finally determine the immunogenicity of the identified B cell epitopes 
displayed in peptides 15 and 121. Peptide 139 is not selected for this study 
because this peptide is not exposed in the HA protein surface and may not 
constitute a target for protective antibody response.  
 Peptide antigens containing peptides 15 and 121 were conjugated with 
carrier protein KLH (500µg of each peptide dissolved in total volume of 1ml PBS). 
Each of six 4-week-old influenza antibody-negative commercial pigs was 
inoculated intranasally with one ml suspension of the KLH-conjugated peptide 15 
and 121 along with heat labile enterotoxin (25 µg LT), while control group 
containing four pigs received 1 ml PBS each intranasally. Two weeks later, all 
piglets received a booster dosage. Blood samples were collected for the serum 
isolation via the jugular vein from piglets 2 weeks after the second round of 
immunization. Peptide-specific antibodies were measured in the ELISA assay as 
described above.  As summarized in Figures 7 and 8, 2 out of 6 inoculated pigs 
showed detectable antibodies against peptide 121 at six weeks following the 
immunization (Figure. 7). All inoculated pigs, however, were found negative in 
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antibody response to peptide 15 during the course of this study (Figure 8). Taken 
together, peptide 121 appears to be immunogenic to pigs; despite that the 
antibody response elicited by this peptide is not uniform among inoculated pigs.  
 
Figure 7. Antibody responses against peptide 121 in pigs. 
Pig sera collected at the date of inoculation and 6 weeks post-inoculation of KLH-
conjugated peptides 15 and 121 or PBS were examined by ELISA for their ability 
to bind to peptide 121 antigen as described in details in materials and methods 
section.  The horizontal broken line represents the OD cut-off value. Background-
corrected OD values above this line are seropositive for peptide antigen. The 
data presented in this figure are representative of three independent 
experiments, each assayed in duplicate. 
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Figure 8. Antibody responses against peptide 15 in pigs. 
Pig sera collected at the date of inoculation and 6 weeks post-inoculation of KLH-
conjugated peptides 15 and 121 or PBS were examined by ELISA for their ability 
to bind to peptide 15 antigen as described in details in materials and methods 
section.  The horizontal broken line represents the OD cut-off value. Background-
corrected OD values above this line are seropositive for peptide antigen. The 
data presented in this figure are representative of three independent 
experiments, each assayed in duplicate. 
 
3.4 Discussion 
 A limitation of the peptide array-based approach is that it cannot identify 
discontinuous conformation-dependent epitopes that may in fact represent 
important antigenic determinants of the HA protein of swine-originated influenza 
 
49 
H1N1pdm09 virus. This approach, however, has been extensively used to 
determine B-cell linear epitopes in viral glycoproteins of several enveloped 
viruses including human immunodeficiency virus (HIV), equine infectious anemia 
virus (a lentivirus), and influenza A virus (Ball et al., 1992; Forsstrom et al., 2015; 
Neurath et al., 1990; Prabakaran et al., 2009; Zhao et al., 2011; Zhou et al., 
2014).  The effectiveness of this approach in the identification of specific B-cell 
linear epitopes that are immunogenic in the native protein antigen may be 
influenced by three major factors. First, the structural and biophysical properties 
of a short protein fragment displayed between the isolated peptide and the native 
protein may be variable, which may lead to differential antibody binding to the 
target. Second, the major histocompatibility complex polymorphisms present in 
an outbred population may influence the recognition of a particular peptide 
antigen by antibodies. Third, host variability may play a role in generation of 
differential activities of host-specific antibodies to same B-cell epitopes.  
 In this study, we used a synthetic peptide array covering the complete 
sequence of the HA protein of swine-originated influenza H1N1pdm09 virus to 
map distinct B-cell epitopes reactive with experimentally infected porcine immune 
sera. The most significant results of this study are the identification of two HA2-
derived peptides (peptide 121 and 139) universally reactive to all tested SIV H1 
cluster sera. Of these two peptides, peptide 139, located in the HA’s 
intracytoplasmic tail, is highly reactive B cell linear determinant.  In addition to 
peptide 121, another surface-exposed epitope represented by peptide 15 also 
emerged but this B cell epitope differs from peptide 121 in that it is only 
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recognized by a limited number of H1 cluster serums.  It is intriguing to note that 
all the identified epitopes fail to be recognized by a H3 subtype serum, indicating 
a subtype-specific nature of the identified antigenic determinants. Furthermore, 
peptide 121-specific antibodies generated from pigs receiving a mixture of 
peptides 15 and 121 are not effective in neutralizing homologous influenza 
H1N1pdm09 virus in both hemagglutination inhibition (HI) and virus neutralization 
assays (data not shown). 
 The results of our study reveal several interesting observations. First, 
peptide antigen, represented by peptide 139 derived from the intracytoplasmic 
tail of the HA protein, is highly immunodominant.  This finding is similar to what 
have been reported previously in retroviral studies showing that the 
intracytoplasmic tail and transmembrane region of retrovirus’s envelope protein is 
strongly antigenic determinant (Ball et al., 1992).  Second, a B cell epitope 
resided in the peptide 15 has been demonstrated in patients recovered from 
influenza H1N1pdm09 infection (Zhao et al., 2011). Despite the similarity, this 
early study revealed that this B cell epitope is capable of inducing high titer non-
neutralizing antibodies in mice, while our study failed to detect measurable 
antibodies against peptide 15 in inoculated pigs. Different adjuvant formulation 
used between these two studies may play a significant role in causing this 
contrasting outcome. Third, it is unfortunate to observe that antibodies generated 
from peptide 121 in pigs possess non-neutralizing capability. It will be interesting 
to determine whether peptide 121-specific antibody can protect swine from 
influenza A virus infect through other antibody-mediated protective mechanism 
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such as antibody-dependent cell-mediated cytotoxicity, which recently emerge as 
one of universal influenza vaccine targets. Finally, neither peptides derived the 
HA2’s helix A nor peptides from the HA2’s long CD helical domain were tested 
positive in pig antisera against various H1 clusters in our ELISA assay. It has 
been reported that low antibody titers against the CD region of the HA2 protein 
were found in some influenza A viruses-infected patients (Wang et al., 2010b).  
These data suggest that using a peptide-based approach to generate antibodies 
against two conserved targets (A and CD helices) may run into a challenge in 
swine. Considering that antibodies to these regions have a universal protection of 
experimental animals against various subtypes, delivery of these targets into 
swine for effective induction of such cross-reactive antibodies may seek a 
different approach such as expression of these antigens through a nanoparticle 
platform.   
 In summary, we have identified two highly conserved epitopes contained 
in peptide peptides 121 and 139 located in HA2 that reacted to all tested SIV H1 
antisera. This study also found another epitope in HA1 peptide 15 that was 
recognized by a subset of H1 antisera. None of these HA1/HA2 peptides of 
H1N1pdm09 were recognized by SIV H3 reference antisera. Results of our study 
shall provide an important foundation for further analyzing the immune response 
against these peptides during natural SIV infection and also provide potential 
peptide substrates for diagnostic assays and for vaccine strategies. 
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CHAPTER 4. FUNCTIONAL STUDY OF A ROLE OF N-TERMINAL HA STEM 
REGION OF SWINE A INFLUENZA VIRUS IN VIRUS REPLICATION AND 
UNIVERSAL SWINE INFLUENZA VACCINE DEVELOPMENT 
 
4.0 Abstract 
Swine influenza virus (SIV) is both a pathogen of economical significance to the 
swine industry and a potential zoonotic organism that may be transmitted to 
humans. A vaccine that can effectively prevent or eliminate the spread of 
influenza virus within and between swineherds is urgently needed. We described 
here the detailed characterization of a role of N-terminal B-loop and CD helix of 
HA2 in swine influenza A virus replication. Results of our experiments 
demonstrated that HA protein of swine influenza virus could tolerate some 
mutations in functionally conserved B-loop and CD helix. These mutations, 
however, have substantially attenuated influenza virus replication in both cell 
lines and porcine primary tracheal epithelial cells. Significantly, we found that 
some B-loop or CD helix mutations generated virus mutants that replicated in 
MDCK and ST cell lines but failed to replicate in primary tracheal epithelial cells, 
thereby suggesting that swine HA protein may function as a viral virulence and 
pathogenesis factor. Finally, intranasal immunization of attenuated N439G 
mutant substantially reduced nasal shedding of both subtypes (H1N1 and H3N2) 
in pigs especially at day 5 post challenge. N439G mutation attenuated the virus 
replication probably by disrupting the formation of triple CD helix. These data 
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demonstrate that intranasal immunization of an attenuated influenza A virus 
can limit virus infection and shedding in pigs exposed to homologous H1N1 as 
well as heterologous H3N2 subtypes.  
 
  
 
55 
4.1 Introduction 
 Influenza A virus is an enveloped virus of the orthomyxoviridae family.   
The genome of the type A virus is separated into 8 independently assorted RNA 
segments, which allows for production of hybrid genotypes during multi-virus 
infections.  Influenza A virus has the unique capacity to undergo genetic variation 
by mutating its major surface protein, hemagglutinin (HA), without changing the 
function of the HA.  These genetic changes, typically associated with HA, render 
current influenza vaccines ineffective against strains different from the vaccine 
strain and call for the periodic production of completely new vaccines to 
overcome antigenic drift or shift (Cox & Subbarao, 2000).  
 Swine influenza virus (SIV) causes an acute respiratory disease in 
pigs.  The pathogen is an important component of the porcine respiratory disease 
complex and by itself can have a significant impact in the swine industry 
(Easterday, 1980; Rajao et al., 2018).  A typical outbreak of respiratory disease 
caused by SIV is characterized by sudden onset, and rapid spread within a herd 
(Vincent et al., 2008).  Clinical symptoms associated with SIV may include 
coughing, sneezing, nasal discharge, elevated rectal temperature, lethargy, 
breathing difficulty, and depressed appetite (Easterday, 1980; Vincent et al., 
2008).  Some studies have suggested that SIV infections can lead to 
reproductive disorders such as abortions (Vincent et al., 2008).  While morbidity 
rates may reach 100% with SIV infections, mortality rates are generally low 
(Easterday, 1980; Vincent et al., 2008).  SIV in pigs can be transmitted to 
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humans, which has raised concerns that such viruses could contribute to the 
generation of pandemic influenza. Such concerns are indeed demonstrated in 
2009 pandemic influenza triggered by a swine-originated H1N1 virus as well as 
in recent transmission into human populations by a variant swine H3N2 virus 
(Maines et al., 2009; Wong et al., 2013).  
 Two subtypes, H1N1 or its variant H1N2 and H3N2, are a major cause of 
worldwide swine influenza (Vincent et al., 2008). There are several antigenic 
clusters or clades within each subtype (Hause et al., 2010; Hause et al., 2012; 
Rajao et al., 2018).  Any subtle changes in the receptor binding site or 
neutralization-sensitive region through evolving viral evolution for replication 
fitness have a negative influence on the effectiveness of a vaccine, which is 
formulated for a particular strain. Additional mutations in N-linked glycosylation of 
HA can promote viral evasion of antibody recognition by altering the 
oligosaccharide layer surrounding HA. Glycan residues can restrict the binding of 
some antibodies to their epitopes, leading to loss of antibody recognition and 
immunogenicity in a phenomenon known as glycan shielding (Wanzeck et al., 
2011). Additionally, mutation and genetic drift occur preferentially at positions in 
the HA globular head that are not protected by glycans (Das et al., 2010). Glycan 
residues also influence receptor binding and consequently can affect viral 
replication kinetics. Our recent work showed that the relocation of the 
hemagglutinin N-linked glycosylation site from N142 to N144 renders swine 
influenza virus δ-cluster viruses resistant to preexisting antibody-mediated 
neutralization (Hause et al., 2012). 
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 Hemagglutinin (HA), the major influenza virus surface protein, is a 
homotrimer, with each monomer consisting of an outer HA1 subunit that is linked 
covalently to a membrane-anchoring HA2 subunit (Wiley & Skehel, 1987). HA1 
binds the virus to its cellular receptors, which are sialic acid residues of 
glycoproteins or glycolipids, and following endocytosis, HA2 mediates the fusion 
of viral and cellular membranes in a pH-dependent manner to permit entry of the 
genome complex into the cell (Bullough et al., 1994a). 
 HA2 constitutes the core machinery that drives virus-cell or cell-cell fusion 
leading to influenza virus entry (Bullough et al., 1994a; Wiley & Skehel, 1987). 
The N-terminal 20 residue of HA2 protein is a fusion peptide (F) that is the most 
highly conserved region in HA2. In addition to the fusion peptide, HA2 consists of 
5 helixes (A, C, D, G, H), 2 β–strands (E and F), and 1 loop (B) (Figure 9). After 
being subjected to a low pH, the fusion peptide gets exposed and inserted into 
the membrane, followed by a cascade of structural rearrangements of HA2. 
These structural rearrangements transform HA2 to post-fusion state (fusogenic 
structure) from a pre-fusion state (pre-fusogenic structure) that accompanies the 
completion of virus-cell fusion event (Figure 9). It has been established that virus-
cell fusion process is largely driven by a trimeric coiled-coil formed by the long 
and central CD helix (residues 75 to 126) in combination with the A helix 
(residues 38 to 58) that packs against the central helical bundle (Bullough et al., 
1994a; Wiley & Skehel, 1987). This structure can be designated as HA2 fusion-
active (Ekiert et al., 2009). 
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Figure 9. Crystal structure of the influenza virus HA protein and structural 
characterization of its rearrangement. 
(a) Overview of a trimeric HA0 precursor, shown as a ribbon diagram. One monomer is 
colored in yellow (HA1 subunit) and red (HA2 subunit) illustrating the locations of 
subdomains. The two other monomers that make up the trimer are shown in blue and 
green. (b) Ribbon diagram of a monomeric, cleaved form of the HA. Featured subdomains 
are highlighted with different colors: helix A (green), loop B (orange), helix C (pink), helix 
CD (blue), helix D (purple), β-sheet EF (cyan), helix G (black) and fusion peptide (red). 
Modified from  Thomas Han and Wayne A. Marasco, Ann N Y Acad Sci. 2011 January; 
1217: 178–190. 
There are several interesting conformational changes associated with the 
formation of a post-fusion HA2 structure following low pH triggering (Bullough et 
al., 1994a; Bullough et al., 1994b; Wiley & Skehel, 1987). One of these changes 
is in the B loop connecting A and CD helices (residues 55 to 76) that are in a 
loop conformation in the native HA2 structure, but become helical during the 
HA2-mediated fusion process. Conversely, residues 106-111, a portion of central 
CD helix, change from helix to a loop structure during the HA2-mediated fusion. 
Another interesting change is that the H helix becomes a disordered structure 
following low pH triggering. Such conformational changes are normally transient 
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during the fusion process and also probably occur in a sequential manner. 
Each of these changes associated with HA2 might be collectively called fusion 
intermediates. 
 Structure and function of these fusion intermediates are likely conserved 
among different influenza A viruses because they are critical to virus entry. It can 
be envisioned that any spatial and temporal disruption, even subtle, in the 
formation of these fusion-active intermediates will block conversion of HA2 to the 
post-fusion conformation and virus fusion and subsequently inhibit virus 
replication. Earlier studies of the mechanism of influenza virus neutralization 
have demonstrated that antibodies targeting the fusion more likely exhibit an 
overall cross-reactive tendency in neutralizing different subtypes whereas 
antibodies targeting receptor binding are strain-specific (Bright et al., 2008; Bright 
et al., 2007; Perrone et al., 2009). This phenomenon has recently been 
confirmed and extended in several independent studies (Bommakanti et al., 
2010; Ekiert et al., 2009; Kashyap et al., 2008; Kashyap et al., 2010; Sui et al., 
2009; Wang et al., 2010b; Wang et al., 2010c). 
 By using similar techniques such as phage display selection on 
recombinant HA antigen either for human influenza virus-specific antibodies or a 
human antibody library, investigators found a handful of antibodies represented 
by CR6261 and F10 that can effectively neutralize multiple subtypes, including 
H1, H2, H5, H6, H8, and H9, and protect mice from lethal challenge with HIN1 
and H5N1 viruses (Ekiert et al., 2009; Kashyap et al., 2008; Kashyap et al., 2010; 
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Sui et al., 2009). Several lines of evidence demonstrated that these antibodies 
target viral fusion machinery largely constituted of HA2, rather than the receptor-
binding site in HA1 (Ekiert et al., 2009; Kashyap et al., 2008; Kashyap et al., 
2010; Sui et al., 2009). It has been shown that CR6261 and F10 bind to different 
conformational epitopes present in the shorter A helical region (residues 38 to 
58) probably in the context of the adjoining region and prevent low pH-triggered 
fusion, thereby neutralizing influenza viruses (Ekiert et al., 2009; Sui et al., 2009). 
In addition to F10 and CR6261, new broad-spectrum protective antibody, 12D1, 
which binds to a liner epitope (70-106 amino acid residues) present in the HA2 
long CD helix, has been recently described (Wang et al., 2010b). The A helix 
consisting of 21 residues (a target of CR6261 and F10) and the CD helix 
consisting of 52 residues (a target of 12D1) are very similar among various 
subtypes of influenza viruses in terms of primary sequence and structure. Thus 
these conserved HA2 structures represent an important target for universal 
vaccine discovery and development against influenza viruses. 
 Despite the significant progress recently made in discovering broadly 
reactive antibodies against divergent influenza viruses, it is not entirely clear why 
CR6261, F10, and 12D1 have been so difficult to identify (Ekiert et al., 2009; Sui 
et al., 2009; Wang et al., 2010b). While very low levels of serum antibody specific 
to 12D1 epitope were detected in human subjects (Wang et al., 2010b), overall 
these antibodies are not frequently induced, either by immunization with 
influenza vaccines or through natural infection. A possible explanation is that the 
neutralizing epitopes present in fusion intermediates of HA2 are transient in 
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nature, existing for a limited period of time - post low pH triggering, but 
disappear after the completion of HA2 conformational changes. Such a short 
time frame may significantly reduce the chance for fusion intermediates to 
present their epitopes to the immune system. Alternatively, HA1 may restrict the 
exposure of epitopes associated with HA2, thereby resulting in a limited immune 
response. It is likely that these scientific challenges should be taken into account 
when rational design of a universal influenza vaccine is performed. 
 Significantly, vaccination with a linear peptide mimicking the CD helix 
provides protection against a subset of distinct viral subtypes in a murine 
influenza model (Wang et al., 2010b). In line with the recent progress toward a 
universal influenza vaccine, a recent study showed that vaccination of mice with 
modified HA2 protein expressed in Escherichi coli protects mice from pathogenic 
influenza challenge (Bommakanti et al., 2010). These elegant studies provided 
proof-of-concept for the feasibility of a HA2-based universal approach in 
stimulation of broad-spectrum immunity, which supports our study here. 
Considering that a stretch of residues within the A helix is similar among different 
subtypes and also reacts with high affinity to CR6161 or F10, it is possible that a 
linear peptide mimicking the A helix can be tested for induction of a CR6261- or 
F10-like neutralizing antibody. However, an epitope that CR6261 or F10 
recognizes is in a conformational state and some of its residues are not 
particularly exposed in native viruses (Ekiert et al., 2009; Sui et al., 2009). The 
cryptic nature of these B-cell epitopes may challenge the linear peptide-based 
approach as one used for generation of 12D1-like antibody responses (Wang et 
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al., 2010b), indicating innovative strategies may be required to present the 
epitope in a native context. Furthermore, despite broad-spectrum activity, 
antibodies derived from the CD peptide immunization seem more efficacious in 
protecting against homologous than heterologous groups of influenza A viruses 
(Wang et al., 2010b), suggesting that further optimization of antigen presentation 
might be needed to make a vaccine candidate equivalently protective against all 
subtypes. 
 In this study we proposed to explore swine influenza virus’s fusion 
machinery as targets for universal swine influenza vaccine development. We 
initially focused on the detailed characterization of SIV variants with mutations on 
the A-helix and CD-helix of HA2 stem region and then selected a vaccine 
candidate from HA2 mutants for evaluation of its protective efficacy against SIV 
H1N1 and H3N2 subtypes in pigs. 
 
4.2 Materials and Methods 
4.2.1 Cell and viruses. 
Swine testicle (ST), Madin-Darby Canine Kidney (MDCK), and 293T human 
embryonic kidney cells were purchased from ATCC. These cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10 % FBS at 37 °C with 
5 % CO2. Primary epithelial cells from porcine trachea were developed from a 
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healthy 3-week old piglet. For viral propagation, fetal bovine serum was 
omitted from the DMEM.   
4.2.2 Influenza reverses genetics system and HA2 mutagenesis 
 H1N1 A/WSN/33 reverse genetics system (RGS) was kindly provided by 
E. Hoffmann, St Jude Children’s Research Hospital (Hoffmann et al., 2000). This 
system contains eight plasmids: pHW181-PB2, pHW182-PB1, pHW183-PA, 
pHW184-HA, pHW185-NP, pHW186-NA, pHW187-M, and pHW188-NS. The full-
length HA gene from H1N1 A/swine/North Carolina/3793/08 (Hause et al., 2012) 
was amplified and cloned into pHW2000 vector that derived H1N1 A/WSN/33 
RGS. A combined RGS that contains seven segments 
(PB1/PB2/PA/NP/NA/M/NS) from WSN/33 system and one HA segment from 
A/swine/North Carolina/3793/08 was used as the template to create single-point 
substitutions targeting the A and CD helical region of the HA2.  We also included 
mutations targeting the B-loop in our mutagenesis. The standard site-direct 
mutagenesis was performed on the HA plasmid using a QuickChange II site-
directed mutagenesis kit (Agilent technologies). 
4.2.3 Production of infectious IAVs by reverse genetics.  
 Recombinant A/WSN/33 displaying SIV HA and its derivatives were 
produced by the standard reverse genetic technique. Briefly, to rescue the 
viruses, 293T and MDCK cells were co-cultured at approximately 70 % 
confluence in 12-well plates and transfected with a mixture of eight plasmids, 
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which were prepared in Trans-LT1 (Mirus) and Opti-MEM I medium according 
to the manufacturer’s instructions. The mixtures were incubated at room 
temperature for 45 min before they were added to the cells. After 6 h culture, 
transfection mixtures were replaced with Opti-MEM I medium followed by an 
additional 18 h incubation at 37 °C. Then, Opti-MEM I medium containing 
tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin (Sigma-Aldrich) at 
a concentration of 1 µg per was added to each well. At 72 h post-transfection, 
viral supernatants were collected, centrifuged at 2000 r.p.m. (Sorvall Legend 
Mach 1.6R, rotor 75003348) for 10 min, which were followed by storage at −80°C 
until further analysis. The resulting viruses were confirmed for introduced 
mutations through RT-PCR coupled with traditional Sanger sequencing 
approach. 
4.2.4 Effects of mutations on the HA binding to erythrocytes.  
 We used this traditional assay to determine whether the introduced 
mutations disrupt the ability of HA to bind to red blood cells, an indicator of 
receptor binding. Wild type and mutants generated with the above procedure 
were diluted in a volume of 50 μl in PBS in 96-well round-bottom microtiter plates 
(Corning-Costar, Cambridge, Mass.). Chicken erythrocytes were washed twice 
with PBS and re-suspended at a concentration of 2% (vol/vol). Erythrocytes (50 
μl) were added to the viruses, and plates were incubated at RT for 2 hrs. The 
highest dilution of the viruses that caused complete hemagglutination was 
considered the HA titration end point.  
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4.2.5 Effects of mutations on HA protein synthesis and cell surface 
expression (trafficking).  
 293T cells were transiently transfected with mutant HA clones in parallel 
with the wild type HA in 6-well culture plates using the Trans-LT1 (Mirus). At 72 h 
post-transfection, cells were fixed with 2% (wt/vol) paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA) followed by permeabilization with 0.2% 
(vol/vol) Triton X-100. Cells were further incubated with a human anti-HA 
monoclonal antibody and goat anti-human secondary antibody conjugated to 
FITC, and was then washed briefly in PBS before quantitative analysis by flow 
cytometer.  Similar measurement to determine the level of HA protein expression 
on the cell surface was conducted for transfected cells without membrane 
perturbation.   
4.2.6 Effects of mutations on viral replication.  
 MDCK and ST and porcine primary tracheal cells were infected in parallel 
with either the WT or the mutants at various multiplicity of infection (MOI). 
Aliquots of the tissue culture supernatant were taken at periodic intervals for 
determining viral replication kinetics. Virus replication experiments were 
conducted three times, each performed in triplicate. 
4.2.7 Animal experimental subjects, clinical evaluation, and sample collection.  
 All swine influenza antibody-negative 6-week old pigs were acquired from 
Midwest research farm located in Minnesota. Upon arrival, these pigs were kept 
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for one week in isolation rooms at Animal research facility, South Dakota State 
University.  The project were reviewed and approved by the institution’s Animal 
Care and Use Committee (IACUC) prior to its being conducted.  Euthanasia 
procedures were compliant with the recommendations of the most recent 
American Veterinary Medical Association (AVMA) Panel on Euthanasia. 
 All piglets were monitored daily for evidence of respiratory disease 
including rectal temperature. Samples of sera and nasal swabs were prepared 
from each pig prior to vaccination.  Serum samples were stored at -20°C until 
they were tested for antibody reactivity in a hemagglutination inhibition (HI) assay 
and an enzyme-linked immunosorbent assay (ELISA), respectively. Samples of 
nasal washes were stored at -80°C until being used to carry our genetic analysis 
of viral RNA by RT-PCR and virus isolation in MDCK, respectively.  
4.2.8 Experimental immunization and virus challenge procedure.  
 Two vaccine candidates were used in this study.  Wild type H1N1 WSN/33 
was used as a control. N439G virus was derived from WSN33 with a porcine HA 
with single-point substitution at HA position 439. The N439G was replicative in 
cell cultures but attenuated. Vaccination/challenge group contained 8 pigs for 
each vaccine candidate, while control (receiving no vaccine and no challenge) 
and challenge (receiving no vaccine but virus challenge) groups had 4 and 8 
pigs, respectively. For challenge, pandemic H1N1 A/Swine/Minnesota/09 and 
A/Swine/Minnesota/2073/2008 were used. Each vaccine or challenge control 
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group was equally split into two sub-groups (4 animals each sub-group) and 
each sub-group received H1N1 and H3N2 challenge, respectively, as described 
below. 
 The first vaccination was conducted by intranasally delivering 104 TCID50 
WSN/33 and 104 attenuated N439G influenza viruses into pigs in vaccination 
groups. The vaccines were sprayed, ½ in each naris, through an insulin syringe 
fitted with a 29 gauge needle.  Piglets were held head vertical, but not 
tranquilized for the procedure. Two weeks later, the second vaccination was 
conducted similarly including same immunization route and dose. For control 
groups, PBS was used for intranasal inoculation into pigs. Two weeks later after 
the second vaccination, 8 vaccinated animals (with WT WSN/33 or N439G) were 
split into two sub-groups (four animals per sub-group) and the pigs in the two 
groups were then challenged intranasally, respectively, with 1 x 106 TCID50 
infectious does of H1N1 A/Swine/Minnesota/09 and 
A/Swine/Minnesota/2073/2008. 8 animals receiving PBS inoculation were also 
split into two-subgroups (four animals each) and each sub-group was challenged 
with two subtypes of swine influenza, respectively.  
 The pigs were monitored daily for clinical symptoms. Half of the pigs (2) in 
each group were euthanized at 3DPC and the remaining animals were 
euthanized at 5DPC. Serum and clinical samples were collected and assessed 
for immune responses and evidence of viral infection in the lungs.  Lung 
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homogenates were collected at 3DPC and 5DPC and prepared for viral 
isolation through cultivation in MDCK cells.  
4.2.9 Serological assays.  
 The hemagglutination inhibition (HI) assay was conducted by following the 
WHO standard procedure. Briefly, 100 μl serum was mixed with 300 μl of 
receptor-destroying enzyme (RDE) (Denka Seiken Co., Ltd., Japan) and 
incubated overnight in a 37°C water bath. The mixture was heated in a 56°C 
water bath for 30 min to inactivate the remaining activity of RDE. After cooling to 
room temperature, 100 μl physiological saline (0.85% NaCl) was added to serum 
so that the final dilution of serum stock was 1:5. To remove nonspecific 
agglutinins, 25 μl of 5% packed chicken red blood cells (RBCs) (Lampire 
Biological Laboratories, Pipersville, PA) was added to 500 μl RDE-treated and 
heat-inactivated sera. After an additional incubation at 4°C for 1 h, the mixture 
was centrifuged at 1,200 rpm for 10 min; the supernatant was collected, 
aliquoted, and frozen at −20°C or directly used in the following assays. 
 Reference antigens were titrated by 2-fold serial dilutions with 50 μl 
physiological saline and then incubated with 50 μl of 0.5% RBCs. Standardized 
antigens of 4 hemagglutination units per 25 μl were prepared based on the 
titration. Pig serum samples and reference sera were diluted serially 2-fold from 
1:5 with 25 μl physiological saline and incubated with 25 μl standardized antigens 
at room temperature for 15 min, followed by the addition of 50 μl of 0.5% RBCs 
before incubating for an additional 30 min. Physiological saline and serum 
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controls, as well as antigen back titration, also were performed for validation. A 
titer of 40 was used as a threshold, i.e., a sample with a titer of less than 40 was 
judged as negative, and those with a titer equal to or higher than 40 were viewed 
as positive. 
 The microneutralization (MN) assay was performed on MDCK cells as 
described in the WHO standard manual. Prior to neutralization, a 50% tissue 
culture infectious dose (TCID50) of reference viruses was determined on MDCK 
cells, and then the viruses were diluted to 200 TCID50/100 μl with DMEM 
containing 2 μg/ml of TPCK-trypsin, 0.3% BSA, and antibiotics. RDE-treated and 
heat-inactivated pig serum samples and reference ferret antisera were 2-fold 
serially diluted with DMEM containing 2 μg/ml of TPCK-trypsin, 0.3% BSA, and 
antibiotics and mixed with 100 μl TCID50 of the reference viruses to react for 1 h 
at 37°C. The mixture was transferred into 96-well plates that contained 100 μl 
MDCK cell suspension (1.5 × 104 cells/well). The plate was incubated overnight 
at 37°C with 5% CO2. Negative and positive serum controls, virus controls, cell 
controls, and virus back titration also were performed to validate procedures and 
results. The cells were fixed with 100 μl of 80% cold acetone at room 
temperature for 10 min and used for ELISA. Briefly, cells were incubated with the 
primary antibody, anti-influenza B virus nucleoprotein antibody (Abcam, 
Cambridge, MA), and then with the secondary antibody, goat anti-mouse IgG-
horseradish peroxidase (HRP) (Sigma-Aldrich, St. Louis, MO), before being 
washed. The substrate ortho-phenylenediamine (OPD) and stop solution then 
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was added. The absorbance (optical density at 490 nm [OD490]) was read and 
recorded for further analysis. 
 
4.3 Results 
4.3.1 Rationale.  
 Our approach was to identify and characterize “stabilized” HA fusion 
intermediates that may present the HA2 subunit to the immune system as it 
exists post low pH triggering but prior to fusogenic structure formation (e.g., 
locked nonfusogenic strategy) (Bullough et al., 1994a; Bullough et al., 1994b; 
Wiley & Skehel, 1987). Through the introduction of appropriate mutations into the 
A-helix and CD-helix, we can render A-helix and CD helix fully accessible to 
immune system. As a result, some HA intermediate candidates can be identified 
and the selected candidate will be tested in a pig pilot study to evaluate 
protection efficacy against infection by swine influenza H1N1 and H3N2 
subtypes.  
4.3.2 Production of HA constructs with mutations in the A and CD helical region 
and B loop.  
 We generated two groups of mutations targeting the large portion of the 
CD helix in the context of swine HA reverse genetics segment by site-directed 
mutagenesis (Figures 10 and 11).  
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Figure 10. Amino acid sequence of portion of HA2 protein (residues 40 to 
129) and substitution mutants generated in this study. 
A portion of the CD helix consists of an unbroken 3-4 heptad repeats extending from 
residues 77 to 90, a spacer surrounding the residue isoleucine at position 91, and another 
the 3-4 heptad repeat. Please note that positions of amino acids here refer to the 
numbering of HA2 subunit.   
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Figure 11. Mutations in CD helix positions in the context of CD helix 
structure. 
 
 The first group consisted of mutations at the helical a/d positions that 
involved substitution of highly conserved residues with known helix breakers as 
such Glycine, resulting in the abrogation of the secondary structure of the trimeric 
coiled-coil. Individual mutations in the first group were I421G, L424G, V428G, 
G431A, I435G, N439G, and L442G (numbering is based on the full-length HA 
protein sequence of SIV H1N1 beginning from the N-termini). The second group 
involved mutations at the e/g positions that will likely disrupt the packing 
interaction between the coiled-coil structure and the A helix. Individual mutations 
in the second group are N425G, K427G, F432G, D434G, W436G, Y438G, 
L443G, and L445G. To ensure that we had a sizable pool of HA2 fusion 
intermediates with desired protein stability and structural integrity for selection 
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toward further evaluation of the vaccine efficacy in pigs, we generated an 
additional panel of mutations targeting the B-segment of HA2 in a way that both 
A helix and CD helix (containing a unique set of neutralizing determinants) are 
not disrupted. Three mutations, K402P, A409P, and K412P targeting the B-loop 
were produced. In summary, total 18 mutants were generated in SIV H1 RGS 
segment, which were confirmed by PCR coupled with traditional Sanger 
sequencing method.  
4.3.3 Effects of single-point HA2 substations on viral infectivity.  
 Co-transfection of 293T/MDCK cells was performed as described in the 
Material and Method section under the identical conditions for WT and all mutant 
RGS plasmids. Harvested supernatants at 72 h post-transfection were passaged 
in MDCK one time and the resultant supernatants were measured for HA activity 
as an indication of the mutation-induced effect on viral infectivity. As summarized 
in Table 5, 7 mutants were successfully rescued and replication-competent, while 
majority of mutants (11 total) were replication-incompetent. Further analysis 
showed that viruses with A409P substitution in the B-loop or D434G substitution 
in the CD helix displayed a WT-like infectivity, indicating that these two mutations 
had no effects on viral infectivity. Furthermore, one virus with L445G mutation 
exhibited a slightly reduced infectivity. Interestingly, four viruses (G431A, I435G, 
N439G, and N425G), all in the CD helix, were significantly attenuated (i.e., 50% 
reduction in HA titer when compared to WT virus). Among them, the virus with 
N439G mutation was most affected with only 25% of WT infectivity observed. 
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Table 5. Effects of HA2 mutations on viral infectivity.  
Viruses Location  Position  Titers Effects  
WT (1+7)   ++++  
K402P B loop  - Loop-helix transition  
A409P B Loop  ++++ Loop-helix transition 
K412P B Loop  - Loop-helix transition 
I421G CD helix a - Triple CD helix formation 
L424G CD helix d - Triple CD helix formation 
V428G CD helix a - Triple CD helix formation 
G431A CD helix d ++ Triple CD helix formation 
I435G CD helix d ++ Triple CD helix formation 
N439G CD helix a + Triple CD helix formation 
L442G CD helix d - Triple CD helix formation 
N425G CD helix e ++ CD-A helix interaction  
K427G CD helix g - CD-A helix interaction 
F432G CD helix e - CD-A helix interaction 
D434G CD helix g ++++ CD-A helix interaction 
W436G CD helix e - CD-A helix interaction 
Y438G CD helix g - CD-A helix interaction 
L443G CD helix e - CD-A helix interaction 
L445G CD helix g +++ CD-A helix interaction 
Note: 1. Summary data from three independent experiments with titers measured in HA 
assay. Viruses were passaged one time in MDCK after 293T/MDCK co-cultures involving 
transfection. 
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2. "++++" means 6-8 log2 of HA units; "+++" 5-6 log2 of HA units; "++" 2-4 log2 of 
HA units; "+" less than 1 log2 of HA units; and "-" with no detectable HA units.    
 
4.3.4 Effects of mutations on viral replication kinetics.  
 Replication kinetics data in MDCK (Figure 12) and ST (Figure 13) 
discriminated viruses into three groups based on their growth curves as a 
function of time following infection.  First group consisted of WT and L445G 
mutant, which replicated at a level higher than rest of mutant viruses.  L445G 
mutation seemed to make the virus gain replication fitness in these two cell lines 
because the mutant replicated slightly better than the WT virus. Second group 
that only contained G431A mutant replicated at an intermediate level between 
WT and attenuated groups. The G431A mutant was attenuated approximately by 
1.0 to 2.0 log when compared to WT group but was more robust in the replication 
than the attenuated group by 1.0 log in the average.  Third group contained 
D434G, I435G, N439G, A409P, and N425G, which were highly attenuated by 2-4 
log when compared to the WT virus and L445G mutant.  
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Figure 12. Effects of mutations on viral replications in MDCK cells. 
Replication kinetics of the WT and HA2 mutant viruses in infected MDCK cells. 
MDCK cells were infected with either the parental WT or the indicated mutant 
virus stock at an MOI of 0.1. Virus production following infection of MDCK cells 
was monitored at various times postinfection by measuring viral activity (TCID50 
per ml) in the culture supernatant. The data presented in this figure are 
representative of at least three independent infections. 
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Figure 13. Effects of mutations on viral replication kinetics in ST cells. 
Replication kinetics of the WT and HA2 mutant viruses in infected ST cells. ST 
cells were infected with either the parental WT or the indicated mutant virus stock 
at an MOI of 0.1. Virus production following infection of ST cells was monitored at 
various times postinfection by measuring viral activity (TCID50 per ml) in the 
culture supernatant. The data presented in this figure are representative of at 
least three independent infections. 
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 To determine the effects of these HA2 mutation on viral replication in 
porcine primary tracheal epithelial cells (Figure 14), the predominant in vivo 
target cell for swine influenza, we next compared the replication kinetics of WT 
and HA2 mutant virus stocks in cultures of porcine primary tracheal cells. Virus 
stocks from WT and mutant viruses were prepared with MDCK cells by 
harvesting medium at 3 days post infection. The titers of the various virus stocks 
were determined for infectivity by using the standard TCID50 assay for MDCK 
cells, and primary lung cells were infected in parallel with either the wild type or 
the HA mutants at a multiplicity of infection (MOI) of 0.1 and assayed for virus 
replication as described above. The data in Figure 14 demonstrated that 
the L445G mutant replicated similarly as the WT virus in infected MDM cells. 
Interestingly, G441A mutant, an intermediate phenotype between the WT and 
significantly attenuated group, was substantially attenuated in primary cells. 
Furthermore, D434G mutant replicated only transiently in primary lung cells. The 
other four mutants (I435G, N439G, A409P, and N425G) replicating modestly in 
MDCK and ST cells failed to replicate in primary cells. These data indicate that 
the some HA2 residues are in fact an important determinant of viral replication in 
natural target cells such as lung epithelial cells, despite the evident lack of their 
influence on viral replication levels in transformed cell lines. Thus, these 
observations suggest in vivo functions of HA2 critical residues in the B-loop and 
CD helix that are not adequately reflected in simple infections of cultured cell 
lines.  
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Figure 14. Effects of HA2 mutations on viral replication kinetics in primary 
porcine tracheal epithelial cells. 
Replication kinetics of the WT and HA2 mutant viruses in primary porcine 
tracheal epithelial cells. Primary cells were infected with either the parental WT or 
the indicated mutant virus stock at an MOI of 1.0. Virus production following 
infection of primary cells was monitored at various times postinfection by 
measuring viral activity (TCID50 per ml) in the culture supernatant. The data 
presented in this figure are representative of at least three independent 
infections. 
 We also determined whether these mutations affected HA protein 
expression by using flow cytometer analysis. As demonstrated in Figure 15, most 
of introduced mutations exhibited little or no effects on HA protein expression.  
Only four mutations showed some minor to moderate effects on HA protein 
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expression, including V428G, D434G, Y438G, and L424G. It seems that there 
is no correlation between HA expression level and viral infectivity. For example, 
D434G affecting HA expression by approximately 20% has resulted in WT-like 
replication phenotype. On the other hands, K402P, K427G, F432G, and W436G 
mutants with a WT-like HA expression level all failed to replication in ST and 
MDCK cell lines.  
 
 
Figure 15. Effects of HA2 mutations on HA protein expression measured by 
FACS analysis. 
293T cells were transfected with equal amounts of the parental WT or single 
residue point-substitution mutant DNA. After 48 h, HA expression was analyzed 
with HA-specific antibody through FACS. The level of HA protein expression by 
WT HA was set at 100%. HA expression for each mutant was normalized by 
comparison with WT. These data represent an average of at least four 
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independent experiments. Experimental variability indicated by standard 
deviation bars. 
4.3.5 Attenuated N439G mutant protects pigs from infection by both 
homologous and heterologous virus challenges.  
 We selected N439G mutant as our vaccine candidate based on the 
following three reasons. First, N439G significantly affected influenza virus 
replication as measured in both ST and MDCK cell lines. Second, this mutation 
rendered virus replication goes undetectable in primary porcine tracheal epithelial 
cells.  Third, this mutation may disrupt the formation of triple CD helix but 
maintain the structural integrity of the A helix and B-loop so antibodies against 
these conserved regions can be produced.  
 Animal experiment for evaluation of N439G-mediated protection efficacy in 
pigs was schematically presented in Figure 16. Two weeks following second 
vaccination, four vaccinates were challenged intranasally with 1 x 106 TCID50 of 
H1N1 A/Swine/Minnesota/09, while the other four vaccinates were intranasally 
challenged with 1 x 106 TCID50 of H3N2 A/Swine/Minnesota/2073/2008. Nasal 
swab samples were collected at 3 DPC for virus isolation on MDCK cells. Also 
two animals from each group were euthanized and lung samples collected for 
virus isolation. At 5 DPC, all animals were euthanized and nasal and lung 
samples were collected for virus isolation.  
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Figure 16. Pig study evaluating protection efficacy of N439G virus against 
infections of H1N1 and H3N2 swine influenza viruses. 
 
 
 Pigs challenged with SIV H1N1 or H3N2 did not exhibit obvious clinical 
symptoms including respiratory distress and nasal or ocular discharge. No 
significant differences between vaccinates and controls was observed with 
regard to rectal temperature and body weight (date not shown). At 5 DPC, piglets 
were euthanized and necropsies were performed.  All animals including controls 
(receiving no vaccination) exhibited none of clinical lung lesions. The lack of 
detectable lung lesions in both vaccinated and non-vaccinated animals 
demonstrates that 11 week-age of these pigs may not be susceptible to SIV 
infection and development of clinical responses.  
 We next determined whether vaccinated animals were protected from 
infection by challenging with viruses.  At 3 DPC, viruses were isolated from nasal 
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washes from all challenged animals. The average 1-log decreases in viral 
load, however, were observed in both N439G and WSN/33 vaccination group 
when challenged with H3N2 (Figure 17). In contrast, no evident reduction in viral 
titers was observed in H1N1 challenge group. Remarkably, a significant 
reduction in viral load was observed at 5 DPC from nasal washes in vaccination 
groups (Figure 18). For example, in N439G group, only residual amount of H3N2 
replication was detected, while more than 2.5 log reduction in viral load observed 
in H1N1 challenged animals. In WSN/33 vaccination group, little amount of H1N1 
replication was found, while more than 2.5 log reduction in viral load observed in 
H3N2 challenged animals. Neither control nor vaccinated animals showed 
detectable viral replication in lungs at both 3 DPC and 5 DPC. Again this may 
reflect that pigs at age of 11 week may not be highly susceptible to SIV infection. 
In summary, by viral load analysis, N439G and WSN/33 vaccination substantially 
protected vaccinated pigs from infections of both H1N1 and H3N2.  
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Figure 17. Viral loads present in nasal swabs of pigs at 3-day post infection 
(DPI). 
The nasal washes were collected from pigs as 3DPC by instilling 2 ml of PBS 
using a sterile 25-to-28-gauge cannula into the nostrils and collecting the washes 
by draining to sterile containers or petri dishes. Nasal washes collected in the 
petri dishes were transferred to 1.5-ml tubes and then centrifuged at 500 × g for 6 
min at 4°C to remove any debris. Serial 10-fold dilutions of the sample were 
inoculated on MDCK cell culture plates after the plates were washed with sterile 
PBS. The inoculated cell culture plates were incubated for 5 days at 37°C. After 5 
days, the infected cell culture plates were washed with PBS, fixed in 80% 
acetone, and allowed to dry. The plates were stained for determinations of virus 
titers in nasal washes by indirect immunofluorescence assay. Virus titration was 
determined using the Reed and Muench formula to find the 50% endpoints 
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Figure 18. Viral loads present in nasal swabs of pigs at 5-day post infection 
(DPI). 
The nasal washes were collected from pigs as 5DPC by instilling 2 ml of PBS 
using a sterile 25-to-28-gauge cannula into the nostrils and collecting the washes 
by draining to sterile containers or petri dishes. Nasal washes collected in the 
petri dishes were transferred to 1.5-ml tubes and then centrifuged at 500 × g for 6 
min at 4°C to remove any debris. Serial 10-fold dilutions of the sample were 
inoculated on MDCK cell culture plates after the plates were washed with sterile 
PBS. The inoculated cell culture plates were incubated for 5 days at 37°C. After 5 
days, the infected cell culture plates were washed with PBS, fixed in 80% 
acetone, and allowed to dry. The plates were stained for determinations of virus 
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titers in nasal washes by indirect immunofluorescence assay. Virus titration 
was determined using the Reed and Muench formula to find the 50% endpoints 
 We next used the standard serological assay to examine virus-specific 
antibody responses in vaccinated animals. HI antibody response was determined 
in serum samples collected from animals prior to vaccination and on the day of 
challenge. 
 
Figure 19. High-titer HI antibodies were elicited in N439G vaccinated pigs. 
Characterization of challenge H1N1 virus-specific HI antibody at the day of 
challenge in pigs vaccinated with WT H1N1 WSN/33 and N439G viruses. The HI 
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antibody titer is expressed as the reciprocal of the highest serum dilution 
showing complete inhibition of agglutination using 4 HAU units/25 µL. Horizontal 
bars show the means antibody titers for group with the range indicated by 
standard error bars. The data presented in this figure are representative of three 
independent experiments, each assayed in duplicate. 
 With 1:40 as a cut-off value, none of unvaccinated PBS or WSN/33 
vaccinated pigs demonstrated detectable anti-H1N1 HI titers (Figure 19). All 
N439G vaccinated animals (had detectable serum HI antibody titers against 
H1N1 antigen.  We did not observe a clear correlation between the presence of 
HI antibody titer and protection from infection, as some WSN/33 vaccinated pigs 
that were protected from virus infection following challenge were negative in HI 
antibody response (i.e., titers of less than 1:40).  
 Together, the above observations indicate that piglets responded well to 
intranasal vaccination with both N439G and WSN/33 viruses, thereby limiting 
infection via the nasal route by both homologous and heterologous SIV 
challenge. These results strongly suggest that the vaccination described in this 
work restricts influenza infection in pigs, and suggests that it may have the 
potential to limit the dissemination of the virus among pigs in a vaccinated herd.  
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4.4 Discussion 
 We report here that HA protein of swine influenza virus can tolerate some 
mutations in the B-loop and CD helix without substantially compromising its 
function. These mutations, however, have significantly attenuated influenza virus 
replication in both cell lines and porcine primary tracheal epithelial cells.  Results 
of our HA mutagenesis experiments reveal several interesting findings. First, 
three mutations (G431A, I435G, and N439G) theoretically designed to disrupt the 
formation of triple helix formation (Bullough et al., 1994a; Bullough et al., 1994b; 
Wiley & Skehel, 1987) do not completely abrogate the replication competency of 
mutant viruses. Second, three mutations (N425G, D434G, and L445G) designed 
to inhibit an interaction between helix A and helix CD (Bullough et al., 1994a; 
Bullough et al., 1994b; Wiley & Skehel, 1987) do not also render mutant viruses 
replication-incompetent.  Third, the virus survives A409P mutation that affects a 
transition from B-loop to B-helix following low pH triggering (Bullough et al., 
1994a; Bullough et al., 1994b; Wiley & Skehel, 1987). These new observations 
should offer new functional insights into future function-structure study of swine 
influenza HA protein. 
 Comparative study of viral replication kinetics between transformed cell 
lines and primary tracheal epithelial cells reveal some interesting differences for 
these mutant viruses. N425G, I435G, N439G, and A409P mutants that replicate 
in MDCK and ST are incapable of replicating in primary cells. It has been thought 
that MDCK and ST are not effective innate immunity-expressing cell lines (Hause 
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et al., 2012; Seitz et al., 2010). The failure of mutant viruses replicating in 
primary cells, not in MDCK and ST cell lines, may suggest that HA protein of 
swine influenza A virus may have a novel anti-host function, which is separable 
from its conserved entry and fusion function.  Several previous studies have 
indeed presented good evidence that HA protein has an important role in 
influenza pathogenesis as well as in communication with host proteins (Bottcher-
Friebertshauser et al., 2014; Cline et al., 2013).  Further investigation of these 
HA mutants may continue to support this emerging theme regarding a role of HA 
in viral pathogenesis. 
 Among 18 single-point mutants, only 7 mutants showed various levels of 
replication whereas other 11 mutants are completely replication-incompetent. 
Also attenuation for 7 mutants can be caused by several potential reasons.  For 
example, these mutations may block virus-cell fusion and as a result inactivate 
viral infectivity. It is possible that mutations may affect functional HA trimer 
formation or stability, which in turn block viral entry to cells. On the other hand, 
there is a possibility that these mutations may affect HA’s interactions with other 
viral proteins such as NA or M2 or M1.  Mechanistic studies towards addressing 
these defects should be pursued in future. 
 Currently available vaccines for swine influenza are killed products 
delivered by intramuscular injection, typically with an adjuvant intended to boost 
the immune response (Van Reeth & Ma, 2013).  Immunization by this method 
stimulates the production of IgG antibodies that circulate in the blood, and 
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neutralize the influenza virus to which they may come in contact.  By 
neutralizing virus circulating in the blood, such antibodies protect various internal 
organs from becoming infected, thus reducing or perhaps eliminating clinically 
observable disease.  However, protective antibodies are a strain-specific so any 
mutations in the receptor binding pocket or antigenic sites or the surrounding 
region will make a strain-specific vaccine not effective to neutralize these viral 
variants (Hause et al., 2010; Hause et al., 2012; Ma et al., 2014; Qiao et al., 
2014). While available for humans, live attenuated swine influenza vaccines have 
not been commercially available until 2017 (Vincent et al., 2012). This vaccine 
candidate with a NS1 truncation appears to confer protection against some 
strains or subtype of swine influenza under experimental conditions. From a 
wealth of studies performed in humans, the live attenuated vaccine approach 
seems to provide broader protection within different subtypes of influenza 
viruses, and may provide heterosubtypic immunity.  However, due to the fact that 
the vaccine strains still retain the ability to replicate, reassortment among vaccine 
strains and field strains may occur, potentially resulting in novel viruses that 
could initiate a global influenza pandemic.  Therefore use of an attenuated SIV 
vaccine would carry a potential risk.  In addition to these concerns, live 
attenuated vaccines used for humans and swine are still not effective in 
stimulating broadly reactive antibodies, which enable to protect swine from 
infections by multiple subtypes or strains.  
 N439G mutation attenuated the virus replication probably by disrupting the 
formation of triple CD helix.  Intranasal immunization of N439G mutant 
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substantially reduced nasal shedding of both subtypes (H1N1 and H3N2) in 
pigs especially at day 5 post challenge. Intriguingly, intranasal immunization of 
H1N1 WSN/33 strain in pigs also resulted in a similar level of protection.  These 
two strains are identical except for the HA segment.  N439G contains a HA 
segment with N439 mutation from a currently circulating swine H1N2 virus, while 
WSN/33 has its native HA segment.  The other seven segments are all derived 
from WSN/33 virus.  Despite further work needed toward dissecting a protective 
mechanism, our current hypothesis is that T cell immunity residing in viral 
structural proteins such as M or NP or antibodies raised against NA protein may 
play a significant role in stimulating the observed cross-subtype protection, which 
will be tested in further studies. Among a panel of 18 HA2 mutants generated in 
this study, 11 mutants are completely lost in infectivity. These mutants may still 
have the potential in serving a good vaccine target for further development.  One 
approach is to express these proteins in baculovirus-based insect cells and then 
test their broad-spectrum efficacy in pigs.  
 Developing a swine influenza vaccine that improves the breadth and 
durability of protection is a high priority. Research work presented here in 
exploring viral fusion as a target for swine universal vaccine development is 
toward this ultimate goal. In addition to HA, investigation of the role of anti-NA 
protein antibodies in protection of swine against swine influenza A virus infection 
is needed. Our present study observed that some pigs possessed no detectable 
HI antibody titers but were protected from infection by vaccination.  This 
intriguing finding suggests that protective antibodies are not traditional 
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neutralizing antibodies and they may provide protection through other 
mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) (He et al., 
2016). In addition to antibody targets, the role of T cell-mediated protective 
immunity in swine influenza infection and diseases should be extensively 
investigated (Townsend et al., 2006).  Our work described here also pinpoints 
that CD4+ and CD8+ T cells may confer to the observed cross-subtype 
protection.  Influenza virus is a moving target; a universal swine influenza 
vaccine needs to incorporate multiple viral components that stimulate both B and 
T cell immune responses, which may provide durable and broad protection for 
swine against multiple influenza strains (Erbelding et al., 2018).  
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